Cancer: principles & practice of oncology
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia u.a.
Lippincott Williams & Wilkins
2005
|
| Ausgabe: | 7. ed. |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | Literaturangaben |
| Beschreibung: | IXXV, 2898, 158 S. zahlr. Ill., graph. Darst. |
| ISBN: | 0781744504 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV019688358 | ||
| 003 | DE-604 | ||
| 005 | 20080602 | ||
| 007 | t | ||
| 008 | 050207s2005 ad|| |||| 00||| eng d | ||
| 020 | |a 0781744504 |9 0-781-74450-4 | ||
| 035 | |a (OCoLC)65978431 | ||
| 035 | |a (DE-599)BVBBV019688358 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 084 | |a XH 1200 |0 (DE-625)152866: |2 rvk | ||
| 245 | 1 | 0 | |a Cancer |b principles & practice of oncology |c ed. by Vincent T. DeVita ... |
| 250 | |a 7. ed. | ||
| 264 | 1 | |a Philadelphia u.a. |b Lippincott Williams & Wilkins |c 2005 | |
| 300 | |a IXXV, 2898, 158 S. |b zahlr. Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 500 | |a Literaturangaben | ||
| 650 | 7 | |a Neoplasias |2 larpcal | |
| 650 | 7 | |a Oncologia |2 larpcal | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Neoplasms | |
| 650 | 4 | |a Oncology | |
| 650 | 0 | 7 | |a Onkologie |0 (DE-588)4075658-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebsforschung |0 (DE-588)4165564-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Onkologie |0 (DE-588)4075658-0 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Krebsforschung |0 (DE-588)4165564-3 |D s |
| 689 | 2 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a DeVita, Vincent T. |e Sonstige |4 oth | |
| 856 | 4 | 2 | |m HEBIS Datenaustausch Mainz |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013016209&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-013016209 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804133132360744960 |
|---|---|
| adam_text | CANCER PRINCIPLES & PRACTICE OF ONCOLOGY 7TH EDITION * * * * * * * + *
%#** #*#** LIPPINCQTT WILLIAMS & WILKINS A WOLTERS KLUWER COMPANY |
PHILADELPHIA * BALTIMORE * NEW YORK * LONDON BUENOS AIRES * HONG KONG *
SYDNEY.* TOKYO CONTENTS PART MOLECULAR BIOLOGY OF CANCER 1 MOLECULAR
METHODS IN ONCOLOGY SECTION 1 AMPLIFICATION TECHNIQUES 3 PAUL M. LIZARDI
IMPROVED ANALYSIS OF MUTATIONS IN ONCOGENES AND TUMOR SUPPRESSOR GENES 3
HIGHLY PARALLELIZED SINGLE-NUCLEOTIDE POLYMORPHISM ASSAYS CAN ALSO BE
USED FOR SOMATIC GENOTYPING 4 INCREASING THE ACCURACY OF SEQUENCE
INFORMATION DERIVED FROM POLYMERASE CHAIN REACTION AMPLIFICATION 5
MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION AMPLIFICATION FOR
DETECTION OF MINIMAL RESIDUAL DISEASE OR VIRAL LOAD 5 MUTATION DETECTION
USING IN SITU HYBRIDIZATION METHODS COUPLED WITH DNA AMPLIFICATION 5
HIGH-THROUGHPUT METHODS FOR MEASURING GENE DOSAGE ALTERATIONS 6 WHOLE
GENOME AMPLIFICATION OF MICRODISSECTED TISSUE 6 , AMPLIFICATION OF
GENOMIC REPRESENTATIONS FOR ANALYSIS OF GENE GAIN/LOSS 6 TUMOR
CLASSIFICATION USING REAL-TIME POLYMERASE CHAIN REACTION TO MEASURE
MESSENGER RNA LEVELS 6 XXLX XXX CONTENTS BIOMARKER DETECTION USING
DNA-AMPLIFIED IMMUNOASSAYS 7 AMPLIFICATION-BASED APPROACHES FOR DNA
METHYLATION ANALYSIS IN CANCER 7 SECTION J RNA INTERFERENCE 8 RICHARD A.
MORGAN BIOCHEMISTRY AND FUNCTION 8 RNA INTERFERENCE IN MAMMALS 10 CANCER
APPLICATIONS 11 SECTION 3 CDNA ARRAYS 13 KEVIN M. BROWN INGRID A.
HEDENFALK JEFFREY M. TRENT DNA MICROARRAYS AND THE MOLECULAR PROFILING
OF HUMAN CANCERS 13 MICROARRAY TECHNOLOGY 13 PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA 15 DIFFUSE LARGE B-CELL LYMPHOMA 18 BREAST CANCER
19 MICROARRAYS, TUMOR AGGRESSIVENESS, AND METASTASIS 21 ARE DNA
MICROARRAYS READY FOR ROUTINE CLINICAL MANAGEMENT OF PATIENTS WITH
CANCER? 22 CONCLUDING REMARKS 24 SECTION 4 TISSUE ARRAYS 26 MARISA
DOLLED-FILHART DAVID L. RIMM TISSUE MICROARRAY CONSTRUCTION 26 TISSUE
MICROARRAY VISUALIZATION 28 TISSUE MICROARRAY ANALYSIS 29 TISSUE
MICROARRAY APPLICATIONS 32 SECTION 5 CYTOGENETICS 34 MAZIN B. QUMSIYEH
YESIM YILMAZ CHROMOSOME STRUCTURE AND FUNCTION 34 CYTOGENETIC METHODS 36
CHROMOSOME ABNORMALITIES IN CANCER 38 DATA MINING IN CANCER CYTOGENETICS
42 SECTION 6 BIOINFORMATICS 43 KENNETH H. BUETOW FLAVORS OF
BIOINFORMATICS 44 BIOMEDICAL INFORMATICS 44 ELECTRONIC INFORMATION
PROVISIONING 44 IN SILICO BIOMEDICAL APPLICATIONS 46 THE FUTURE 50
CONTENTS XXXI 51 GENOMICS AND PROTEOMICS KATHERINE R. CALVO EMANUEL F.
PETRICOIN III LANCE A. LIOTTA UNDERSTANDING CANCER AT THE MOLECULAR
LEVEL: AN EVOLVING FRONTIER GENETIC MECHANISMS OF CANCER PROGRESSION 51
POSTGENOME CHALLENGE FOR MOLECULAR MEDICINE 57 TISSUE MICRODISSECTION
TECHNOLOGY BRINGS MOLECULAR ANALYSIS TO THE TISSUE LEVEL 58
COMPLEMENTARY DNA MICROARRAYS AS A TOOL TO ANALYZE GENE EXPRESSION
PATTERNS IN HUMAN CANCER BEYOND FUNCTIONAL GENOMICS TO CANCER PROTEOMICS
63 MOLECULAR DIAGNOSTICS AND INDIVIDUALIZED CANCER THERAPY 63 SERUM
PROTEOMICS 67 51 59 MOLECULAR TARGETS IN ONCOLOGY. 73 SECTION 1 SIGNAL
TRANSDUCTION SYSTEMS 73 CHRISTOPHER L. CARPENTER LEWIS C. CANTLEY
SENSORY MACHINERY: LIGANDS AND RECEPTORS 73 PROPAGATION OF SIGNALS TO
THE CELL INTERIOR 76 EFFICIENCY AND SPECIFICITY: FORMATION OF
MULTIPROTEIN SIGNALING COMPLEXES 80 REGULATION OF PROTEIN LEVELS:
TRANSCRIPTION, TRANSLATION, AND PROTEOLYSIS 81 SECTION 2 CELL CYCLE 83
STEVEN I. REED CELL-CYCLE ENGINE 83 REGULATION OF THE CELL CYCLE 87 CELL
CYCLE AND CANCER 90 CELL CYCLE AS A TARGET FOR THERAPY CONCLUSION 94 93
SECTION 13 APOPTOSIS 95 SANDRA S. ZINKEL STANLEY J. KORSMEYER GENETICS
OF CELL DEATH 95 BCL-2 FAMILY 95 CRITICAL ROLE OF APOPTOSIS IN TISSUE
HOMEOSTASIS 98 CASPASES 99 DEATH RECEPTORS 99 APOPTOSOME 99 INHIBITORS
OF APOPTOSIS 101 ROLE OF INTRACELLULAR ORGANELLES: MITOCHONDRIA AND
ENDOPLASMIC RETICULUM CELL PROLIFERATION AND APOPTOSIS 101 POSSIBILITIES
FOR THERAPEUTIC INTERVENTION 102 CONCLUSION 102 LOLI XXXII CONTENTS
SECTION 4 TELOMERASE 105 KWOK-KIN WONG RONALD A. DEPINHO TELOMERES 105
TELOMERASE STRUCTURE, REGULATION, AND FUNCTION 106 CRISIS, TELOMERASE
REACTIVATION, AND ALTERNATIVE LENGTHENING OF TELOMERES 106 TELOMERE
MAINTENANCE AND CANCER 107 AGING AND CANCER 107 TELOMERE DYNAMICS,
INFLAMMATORY DISEASES, AND CANCER 108 TELOMERE STATUS AS A BIOMARKER FOR
CANCER 109 TELOMERASE AND TELOMERE MAINTENANCE AS THERAPEUTIC TARGETS
109 RATIONAL CLINICAL TRIAL DESIGNS OF TELOMERE- AND TELOMERASE- BASED
THERAPEUTICS 111 INVASION AND METASTASES 113 WILLIAM G.
STETLER-STEVENSON TUMOR PROGRESSION AND GENETIC INSTABILITY 113 ORIGINS
OF METASTATIC TUMOR CELLS 114 MICROARRAY ANALYSIS OF TUMOR PROGRESSION
AND METASTASIS 115 TUMORIGENESIS AND METASTASIS ARE UNDER SEPARATE
GENETIC CONTROL: TUMOR SUPPRESSOR GENES 116 METASTATIC CASCADE 117 , -
TUMOR MICROENVIRONMENT: DETERMINANT OF METASTATIC POTENTIAL AND SITE OF
METASTASIS 118 TUMOR CELL MOTILITY 119 TUMOR INVASION OF THE BASEMENT
MEMBRANE 119 INITIATION OF CELL MIGRATION 119 CELL-CELL ADHESION:
METASTASIS SUPPRESSOR 120 V CELL MATRIX INTERACTIONS AND TUMOR CELL
MIGRATION 121 ROLE OF CD44 IN TUMOR INVASION AND METASTASIS 121 ROLE OF
INTEGRINS IN TUMOR PROGRESSION 722 CELL MIGRATION 124 PROTEASES IN TUMOR
CELL INVASION 125 CONCLUSION 126 ANGIOGENESIS 129 ISAIAH J.FIDLER ROBERT
R. LANGLEY ROBERT S. KERBEL LEE M. ELLIS _ NEOPLASTIC ANGIOGENESIS 129
PHENOTYPIC DIVERSITY OF ORGAN-SPECIFIC ENDOTHELIAL CELLS 131 TUMOR
VASCULATURE 132 HOST-MEDIATED ANGIOGENESIS 132 OVERVIEW OF
ANTIANGIOGENIC AND ANTIVASCULAR THERAPIES 133 ANTIVASCULAR THERAPY FOR
BONE METASTASIS 134 CLINICAL STUDIES OF IMATINIB 135 DISCREPANCY BETWEEN
RESULTS OF PRECLINICAL AND CLINICAL TRIALS 135 CONTENTS XXXIII BASIC
PRINCIPLES FOR DESIGN OF CLINICAL TRIALS OF ANTIANGIOGENIC AGENTS 135
CONCLUSION 136 6 CANCER IMMUNOLOGY . 139 NICHOLAS P. RESTIFO JOHN R.
WUNDERLICH ANTITUMOR T CELLS 140 BIOLOGIC SOURCES OF TUMOR-ASSOCIATED
ANTIGENS 140 PRESENTATION OF TUMOR ANTIGENS TO T CELLS 141 ROLE OF
ANTIGEN-PRESENTING CELLS IN ACTIVATING ANTITUMOR T CELLS 146 T-CELL
RECOGNITION OF TUMOR ANTIGENS 148 MATURATION OF ANTITUMOR T CELLS 149
ACTIVATION OF MATURE ANTITUMOR T CELLS 150 ACTIVATION STATES OF
ANTITUMOR T CELLS 154 FUNCTIONS OF MATURE ANTITUMOR T CELLS 155
CONCLUSION 157 PART 2 PRINCIPLES OF ONCOLOGY ETIOLOGY OF CANCER: VIRUSES
165 SECTION 1 RNA VIRUSES 165 GARY L. BUCHSCHACHER, JR FLOSSIE
WONG-STAAL RETROVIRTFSES: BACKGROUND, REPLICATION CYCLE, AND MOLECULAR
GENETICS 165 MECHANISMS OF RETROVIRAL ONCOGENESIS 166 HUMAN
T-LYMPHOTROPIC VIRUS TYPE 1 168 HUMAN T-LYMPHOTROPIC VIRUS TYPE 2 169
HUMAN IMMUNODEFICIENCY VIRUS 169 HEPATITIS C VIRUS 171 SECTION 2 DNA
VIRUSES 173 PETER M. HOWLEY DON GANEM ELLIOT KIEFF HEPADNAVIRUSES AND
HEPATOCELLULAR CARCINOMA 174 PAPILLOMAVIRUSES AND HUMAN CANCER 175 J
EPSTEIN-BARR VIRUS 180 KAPOSI S SARCOMA-ASSOCIATED HERPESVIRUS 181
SIMIAN VACUOLATING VIRUS 40 AND THE HUMAN POLYOMAVIRUSES 183 XXXIV
CONTENTS 8 ETIOLOGY OF CANCER: CHEMICAL FACTORS 185 STUART H. YUSPA
PETER G. SHIELDS NATURE OF CHEMICAL CARCINOGENS: CHEMISTRY AND
METABOLISM 185 ANIMAL MODEL SYSTEMS AND CHEMICAL CARCINOGENESIS 186 DNA
REPAIR PROTECTS THE HOST FROM CHEMICAL CARCINOGENS 187 GENETIC
SUSCEPTIBILITY TO CHEMICAL CARCINOGENESIS 187 DETERMINATION OF CHEMICAL
CARCINOGENS FOR HUMANS AND POPULATION- BASED RISK ASSESSMENT 187
CHEMICAL CARCINOGENESIS AND CANCER RISK 187 TUMOR SUPPRESSOR GENES IN
HUMAN CANCER 189 TOBACCO SMOKING AND CANCER RISK 190 9 ETIOLOGY OF
CANCER: TOBACCO USE. . . J 193 GRAHAM A. COLDITZ LAURIE B. FISHER
EFFECTS OF TOBACCO USE AND CESSATION ON CANCER RISK 193 EFFECT OF
TOBACCO USE ON CARDIOVASCULAR DISEASE 196 CIGARS, PIPES, AND SMOKELESS
TOBACCO 196 SECONDHAND TOBACCO SMOKE 197 NATIONAL TRENDS IN SMOKING
PREVALENCE 197 DISPARITIES IN ACTIVE TOBACCO USE AND CESSATION 197
CIGARETTE PRODUCT MODIFICATION*HARM REDUCTION 198 TOBACCO AND NICOTINE
ADDICTION 198 ROLE OF THE CLINICIAN 198 = STRATEGIES FOR TOBACCO
CONTROL 198 CONCLUSION 198 10 ETIOLOGY OF CANCER: PHYSICAL FACTORS . . .
201 ROBERT L. ULLRICH INTERACTIONS OF RADIATION WITH CELLS AND TISSUES
202 ULTRAVIOLET LIGHT 277 ASBESTOS 213 11 EPIDEMIOLOGY OF CANCER . 217
SECTION 1 EPIDEMIOLOGIC METHODS 217 , XIAOMEI MA ; MARGARET A. TUCKER
DESCRIPTIVE STUDIES 275 X - CONTENTS XXXV ANALYTIC STUDIES 279,,
INTERPRETATION OF EPIDEMIOLOGIC FINDINGS 222 SPECIAL TOPIC: MOLECULAR
AND GENETIC EPIDEMIOLOGY 223 SECTION 2 CANCER STATISTICS 226 AHMEDIN
JEMAL ELIZABETH M. WARD MICHAEL J. THUN MEASURES OF THE CANCER BURDEN
226 DATA SOURCES AND AGE STANDARDIZATION 230 TEMPORAL TRENDS 232
DEMOGRAPHIC AND GEOGRAPHIC PATTERNS 234 ISSUES IN THE INTERPRETATION AND
UNDERSTANDING OF TEMPORAL TRENDS 238 CONCLUSION 240 12 PRINCIPLES OF
SURGICAL ONCOLOGY SECTION 1 243 GENERAL ISSUES 243 STEVEN A. ROSENBERG
HISTORICAL PERSPECTIVE 243 ANESTHESIA FOR ONCOLOGIC SURGERY 244
DETERMINATION OF OPERATIVE RISK 246 ROLES FOR SURGERY 249 SURGICAL
ONCOLOGIST 252 SECTION 2 LAPAROSCOPIC SURGERY 253 ALBERT S. KO ALAN T.
LEFOR PHYSIOLOGY OF LAPAROSCOPY 253 PORT-SITE METASTASES 255 LAPAROSCOPY
IN THE DIAGNOSIS OF MALIGNANCY 257 LAPAROSCOPY IN THE STAGING OF
MALIGNANCY 258 LAPAROSCOPY IN THE TREATMENT OF MALIGNANCY 263
LAPAROSCOPY IN THE PALLIATION OF MALIGNANCY 265 CONCLUSION 265 13
PRINCIPLES OF RADIATION ONCOLOGY. 267 PHILIP P. CONNELL MARY K. MARTEL
SAMUEL HELLMAN BIOLOGIC ASPECTS OF RADIATION ONCOLOGY 267 PHYSICAL
ASPECTS OF RADIATION ONCOLOGY 276 CLINICAL ASPECTS OF RADIATION ONCOLOGY
285 XXXVI CONTENTS 14 PRINCIPLES OF MEDICAL ONCOLOGY. 295 EDWARD CHU
VINCENT T. DEVITA, JR HISTORICAL PERSPECTIVE 295 CLINICAL APPLICATION OF
CHEMOTHERAPY 296 CLINICAL END POINTS IN EVALUATING RESPONSE TO
CHEMOTHERAPY 297 CANCER CELL KINETICS AND RESPONSE TO CHEMOTHERAPY 298
PRINCIPLES GOVERNING THE USE OF CHEMOTHERAPY 298 CONCEPT OF DOSE
INTENSITY 300 APOPTOSIS, CELL-CYCLE CONTROL, AND RESISTANCE TO
CHEMOTHERAPY 302 15 PHARMACOLOGY OF CANCER CHEMOTHERAPY 307 SECTION 1
DRUG DEVELOPMENT 307 EDWARD CHU DRUG DISCOVERY 307 COMBINATORIAL
CHEMISTRY 309 DRUG SCREENING 322 MOLECULARLY TARGETED SCREENING 322
PRECLINICAL PHARMACOLOGY 323 FORMULATION STUDIES 324 PRECLINICAL
TOXICOLOGY 325 CLINICAL DEVELOPMENT 325 CONCLUSION 326 , SECTION 2
PHARMACOKINETICS 317 CHRIS H. TAKIMOTO INTRODUCTION 327 PHARMACOKINETIC
CONCEPTS 329 PHARMACODYNAMIC CONCEPTS 323 SPECIAL TOPICS IN
PHARMACOKINETICS AND PHARMACODYNAMICS 324 PHARMACOKINETICS AND
PHARMACODYNAMICS IN ONCOLOGY DRUG DEVELOPMENT 325 CONCLUSION 326 SECTION
3 PHARMACOGENOMLCS 327 HOWARD L. MCLEOD BOON-CHER GOH PHARMACOGENOMICS
OF CHEMOTHERAPY DRUG TOXICITY 327 PHARMACOGENOMICS OF TUMOR RESPONSE 330
CONCLUSION 332 SECTION 4 ALKYLATING AGENTS 332 O. MICHAEL COLVIN HENRY
S. FRIEDMAN HISTORY OF THE ALKYLATING AGENTS 332 CONTENTS XXXVII
CHEMISTRY AND CYTOTOXICITY OF ALKYLATING AGENTS 332 CLASSES OF
ALKYLATING AGENTS AND THEIR PROPERTIES 332 MECHANISMS OF TOXICITY AND
DRUG RESISTANCE 338 COMMON TOXICITIES OF ALKYLATING AGENTS 340 SECTION 5
CISPLATIN AND ITS ANALOGUES 344 STEVEN W. JOHNSON PETER J. O DWYER
HISTORY 344 PLATINUM CHEMISTRY 345 NOVEL PLATINUM COMPLEXES 345
MECHANISM OF ACTION 347 MECHANISMS OF RESISTANCE 349 CLINICAL
PHARMACOLOGY 352 FORMULATION AND ADMINISTRATION 354 TOXICITY 354 SECTION
6 ANTIMETABOLITES 358 SHIVAANIKUMMAR VANITA NORONHA EDWARD CHU
METHOTREXATE 358 NEW ANTIFOLATES 362 SECTION 7 TOPOISOMERASE INTERACTIVE
AGENTS 375 CHRIS H. TAKIMOTO MAMMALIAN TOPOISOMERASES 375 MECHANISM OF
ACTION OF TOPOISOMERASE INTERACTIVE AGENTS 377 CAMPTOTHECINS 377
EPIPODOPHYLLOTOXINS 381 ANTHRACYCLINES AND RELATED COMPOUNDS 384 OTHER
TOPOISOMERASE INTERACTIVE AGENTS 388 SECONDARY MALIGNANCIES AND
TOPOISOMERASE TARGETING THERAPIES 389 SECTION 8 ANTIMICROTUBULE AGENTS
390 ERIC K. ROWINSKY ANTHONY W. TOLCHER MICROTUBULES 390 VINCA ALKALOIDS
392 TAXANES 398 ESTRAMUSTINE PHOSPHATE 407 NOVEL COMPOUNDS TARGETING
MICROTUBULES 420 NOVEL COMPOUNDS TARGETING MITOTIC MOTOR PROTEINS 422
SECTION 9 MISCELLANEOUS CHEMOTHERAPEUTIC AGENTS MEHMET SITKICOPUR MICHAL
G. ROSE EDWARD CHU L-ASPARAGINASE 426 416 XXXVIII CONTENTS BLEOMYCIN 427
IMATINIB MESYLATE 427 GEFITINIB 428 BORTEZOMIB 420 16 PHARMACOLOGY OF
CANCER BIOTHERAPEUTICS 423 SECTION 1 INTERFERONS 423 VERNON K. SONDAK
BRUCE G. REDMAN INTERFERON INDUCTION 423 BIOLOGIC EFFECTS OF INTERFERONS
424 CLINICAL TOXICITY OF INTERFERON ADMINISTRATION 426 POTENTIAL DRUG
INTERACTIONS 427 ONCOLOGIC APPLICATIONS OF INTERFERONS 427 CONCLUSION
429 SECTION 2 INTERLEUKIN-2 431 JAMES W. MIER MICHAEL B. ATKINS
ISOLATION, CHARACTERIZATION, AND CLONING OF INTERLEUKIN-2 432 I(
INTERLEUKIN-2 RECEPTOR 432 INTERLEUKIN-2-ACTIVATED SIGNALING PATHWAYS
432 IN VITRO EFFECTS OF INTERLEUKIN-2 432 PRECLINICAL STUDIES WITH
INTERLEUKIN-2 IN TUMOR-BEARING MICE 432 CLINICAL APPLICATIONS OF
INTERLEUKIN-2 432 CONCLUSION 437 SECTION 3 HISTONE DEACETYLASE
INHIBITORS: NEW TARGETED ANTICANCER DRUGS 439 PAUL A. MARKS VICTORIA M.
RICHON THOMAS A. MILLER WM. KEVIN KELLY ;* CHROMATIN STRUCTURE 439
HISTONE DEACETYLASES AND HISTONE ACETYL TRANSFERASES 439 HISTONE
ACETYLTRANSFERASES AND HISTONE DEACETYLASE INHIBITORS AND HUMAN CANCERS
439 , R L HISTONE DEACETYLASE INHIBITORS 442 ACTIVITY OF HISTONE
DEACETYLASE INHIBITORS 442 CLINICAL TRIALS WITH HISTONE DEACETYLASE
INHIBITORS 443 CONCLUSION AND PERSPECTIVES 444 SECTION 4 MONOCLONAL
ANTIBODIES 445 JONATHAN D. CHENG GREGORY PAUL ADAMS MATTHEW K. ROBINSON
LOUIS M. WEINER IMMUNOGLOBULIN STRUCTURE 446 CONTENTS XXXLX FACTORS
REGULATING ANTIBODY-BASED TUMOR TARGETING 447 UNCONJUGATED ANTIBODIES
448 IMMUNOCONJUGATES 452 PRETARGETED ANTIBODY CONJUGATES 453
UNCONJUGATED ANTIBODIES WITH CLINICAL ACTIVITY IN SOLID TUMORS 453
CONCLUSION 454 17 PHARMACOLOGY OF ENDOCRINE MANIPULATION 457 MATTHEW P.
GOETZ CHARLES ERLICHMAN CHARLES L. LOPRINZI SELECTIVE ESTROGEN RECEPTOR
MODULATORS 457 MEDROXYPROGESTERONE AND MEGESTROL 462 AROMATASE
INHIBITORS 462 GONADOTROPIN-RELEASING HORMONE ANALOGUES 464
ANTIANDROGENS 464 FLUOXYMESTERONE 465 DIETHYLSTILBESTROL AND ESTRADIOL
(ESTRACE) 465 OCTREOTIDE 466 18 DESIGN AND ANALYSIS OF CLINICAL TRIALS
471 RICHARD M. SIMON PHASE I CLINICAL TRIALS 472 PHASE II CLINICAL
TRIALS 473 DESIGN OF PHASE III CLINICAL TRIALS 478 ANALYSIS OF PHASE III
CLINICAL TRIALS 483 PART 3 PRACTICE OF ONCOLOGY 19 CANCER PREVENTION:
PREVENTING TOBACCO-RELATED CANCERS 493 HOWARD K. KOH ALAN C. GELLER
TOBACCO AND NICOTINE ADDICTION 493 HEALTH EFFECTS 493 SMOKING RATES AND
TRENDS 494 I ADULTS 494 CHILDREN, ADOLESCENTS, AND COLLEGE STUDENTS 495
XL CONTENTS CIGARETTE PRODUCT MODIFICATION 495 SPIT TOBACCO 496 CIGARS
496 ENVIRONMENTAL TOBACCO SMOKE 496 TOBACCO INDUSTRY ADVERTISING
STRATEGIES 497 STRATEGIES FOR TOBACCO CONTROL 498 INDIVIDUAL APPROACHES
498 CLINICIAN S ROLE 498 NICOTINE REPLACEMENT THERAPY 499 SPECIAL
POPULATIONS 500 NATIONAL ACTION PLAN FOR TOBACCO CESSATION 500 TOBACCO
RESTRICTIONS AT THE POLICY LEVEL 500 TOBACCO TAXES THAT FUND DEDICATED,
COMPREHENSIVE STATEWIDE TOBACCO CONTROL PROGRAMS 500 MASS MEDIA AND
COUNTER-ADVERTISING 502 TOBACCO LITIGATION, TOBACCO SETTLEMENT, AND
INTERNATIONAL TREATIES 502 PROPOSED U.S. FOOD AND DRUG ADMINISTRATION
REGULATIONS 502 CONCLUSION 503 20 CANCER PREVENTION: DIET AND
CHEMOPREVENTIVE AGENTS 507 SECTION 1 DIETARY FAT 507 WALTER C, WILLETT
FAT AND BREAST CANCER 508 FAT AND COLON CANCER 509 FAT AND PROSTATE
CANCER 520 FAT AND OTHER CANCERS 52 2 CONCLUSION 522 V SECTION 2 DIETARY
FIBER 514 KARIN B. MICHELS DIET AND CANCER ETIOLOGY 524 PROPERTIES OF
DIETARY FIBER 524 OBSERVATIONAL STUDIES AND CLINICAL TRIALS 524 TYPES OF
DIETARY FIBER 525 CALCULATION OF FIBER INTAKE 525 DIETARY FIBER AND
COLORECTAL CANCER 525 FIBER INTAKE AND COLORECTAL ADENOMAS 526 FIBER
INTAKE AND BREAST CANCER 526 DIETARY FIBER AND STOMACH CANCER 526 TIMING
OF DIET 52 7 CONCLUSION 527 SECTION 3 FRUIT AND VEGETABLE CONSUMPTION
518 KARIN B. MICHELS FRUITS AND VEGETABLES 528 DIET ASSESSMENT
INSTRUMENTS 528 * CONFOUNDING 528 FRUIT AND VEGETABLE CONSUMPTION AND
COLORECTAL CANCER 528 V - CONTENTS XLI FRUIT AND VEGETABLE CONSUMPTION
AND STOMACH CANCER 528 FRUIT AND VEGETABLE CONSUMPTION AND BREAST CANCER
529 FRUIT AND VEGETABLE CONSUMPTION AND LUNG CANCER 529 MICRONUTRIENT
COMPONENTS OF FRUITS AND VEGETABLES AND CANCER 529 CONCLUSION 520
SECTION 4 RETINOIDS, CAROTENOIDS, AND MICRONUTRIENTS 521 SUSAN T. MAYNE
SCOTT M. LIPPMAN HISTORICAL PERSPECTIVE 522 RETINOID BIOLOGY AND
PHARMACOLOGY 522 CAROTENOID BIOLOGY AND ACTIONS 522 CLINICAL TRIALS 523
TRANSLATIONAL AND INTERMEDIATE END POINT STUDIES IN RETINOID
CHEMOPREVENTION OTHER RETINOIDS AND CAROTENOIDS 533 CONCLUSION 533 532
SECTION 5 DIETARY CARCINOGENS 536 PETER GREENWALD NATURALLY OCCURRING
DIETARY CARCINOGENS 536 PRODUCTS OF FOOD PREPARATION AND PROCESSING 538
SYNTHETIC CARCINOGENS IN THE DIET 540 FUTURE RESEARCH NEEDS 540 SECTION
6 CYCLOOXYGENASE INHIBITORS 541 MICHAEL J. THUN S. JANE HENLEY
PHARMACOLOGY OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS 542 TOXICITY OF
NONSTEROIDAL ANTIINFLAMMATORY DRUGS 542 HISTORY OF THE INFLAMMATION
HYPOTHESIS 542 NONSTEROIDAL ANTIINFLAMMATORY DRUGS IN RELATION TO OTHER
CANCERS MECHANISMS OF CANCER INHIBITION 544 MOLECULAR TARGET(S) 546
ONGOING RANDOMIZED CLINICAL TRIALS 546 IMPLICATIONS FOR RESEARCH AND
CLINICAL PRACTICE 546 CONCLUSION 548 543 SECTION 7 PHYSICAL ACTIVITY AND
BODY WEIGHT GRAHAM A. COLDITZ KATHLEEN YAUS WOLIN PHYSICAL ACTIVITY 549
OBESITY 552 CONCLUSION 553 549 21 CANCER PREVENTION: ROLE OF SURGERY IN
CANCER PREVENTION RICHARD M. SHERRY MULTIPLE ENDOCRINE NEOPLASIA TYPE 2
AND FAMILIAL MEDULLARY THYROID CARCINOMA 555 555 XLII CONTENTS BARRETT S
ESOPHAGUS AND ESOPHAGEAL CANCER 556 HEREDITARY DIFFUSE GASTRIC CANCER
558 COLORECTAL CANCER 558 BREAST CANCER 562 OVARIAN CANCER 563
TESTICULAR CANCER AND CRYPTORCHIDISM 564 22 CANCER SCREENING 567 BARBARA
K. RIMER JOELLEN M. SCHILDKRAUT ROBERT A. HIATT WHAT IS CANCER
SCREENING? 567 EVALUATION OF A SCREENING TEST 568 BREAST CANCER
SCREENING 569 CERVICAL CANCER SCREENING 572 COLORECTAL CANCER SCREENING
573 SKIN CANCER SCREENING 574 PROSTATE CANCER SCREENING 574 LUNG CANCER
SCREENING 576 ADHERENCE TO CANCER SCREENING 577 FUTURE OF SCREENING 577
23 ADVANCED MOLECULAR DIAGNOSTICS 581 JOSE C. COSTA PAUL M. LIZARDI V
PRESENT IMPACT OF NOVEL TECHNOLOGIES ON CLINICAL PRACTICE 582 CHARTING
THE FUTURE 584 CONCLUSION 586 24 ADVANCED IMAGING METHODS 589 SECTION 1
FUNCTIONAL AND METABOLIC IMAGING 589 HEDVIG HRICAK OGUZAKIN MICHELLE S.
BRADBURY LAURA LIBERMAN LAWRENCE H. SCHWARTZ STEVEN M. LARSON IMAGING
MODALITIES 589 THERAPEUTIC RESPONSE ASSESSMENT 594 BRAIN AND HEAD/NECK
CANCERS 595 LUNG CANCER 597 LYMPHOMA 600 BREAST CANCER 602
HEPATOBILIARY CANCER 604 V COLORECTAL CANCER 605 CONTENTS XLIII
GYNECOLOGIC CANCER 607 ENDOMETRIAL CANCER 607 CERVICAL CANCER 608
OVARIAN CANCER 609 PROSTATE CANCER 620 MOLECULAR IMAGING IN ONCOLOGY 622
SECTION 2 INTERVENTIONAL RADIOLOGY 617 ANNE M. COVEY KAREN T. BROWN
PERCUTANEOUS BIOPSY 627 CENTRAL VENOUS ACCESS 629 GASTROINTESTINAL
PROCEDURES 629 GENITOURINARY PROCEDURES 620 BILIARY PROCEDURES 623 CHEST
INTERVENTIONS 626 INFERIOR VENA CAVA FILTERS 629 ASCITES 630 ABSCESS
DRAINAGE 632 EMBOLOTHERAPY FOR HEPATIC NEOPLASMS 63 2 TUMOR ABLATION 632
EMERGING THERAPIES AND FUTURE DIRECTIONS 634 25 CANCER DIAGNOSIS:
ENDOSCOPY 637 SECTION 1 GASTROINTESTINAL ENDOSCOPY 637 IRVING WAXMAN
UPPER ENDOSCOPY 637 COLONOSCOPY 640 ENDOSCOPIC ULTRASONOGRAPHY 642 SMALL
BOWEL ENDOSCOPY AND CAPSULE ENDOSCOPY 642 ENDOSCOPIC RETROGRADE
CHOLANGIOPANCREATOGRAPHY 642 SECTION 2 RESPIRATORY TRACT 643 DAO M.
NGUYEN RONALD M. SUMMERS STEVEN E. FINKELSTEIN BRONCHOSCOPY 643 VIRTUAL
BRONCHOSCOPY 645 CERVICAL MEDIASTINOSCOPY AND ANTERIOR MEDIASTINOTOMY
647 VIDEO-ASSISTED THORACOSCOPY 648 26 CANCER OF THE HEAD AND NECK 653
SECTION 1 MOLECULAR BIOLOGY OF HEAD AND NECK TUMORS 653 DAVID
SIDRANSKY GENETIC SUSCEPTIBILITY 653 XLIV CONTENTS CYTOGENETIC
ALTERATIONS 653 PROTOONCOGENES 654 SUPPRESSIVE GROWTH REGULATION 655
TUMOR SUPPRESSOR GENES 655 FIELD CANCERIZATION 657 MOLECULAR
EPIDEMIOLOGY 658 HUMAN PAPILLOMAVIRUS 658 DIAGNOSTICS 658 SECTION 2
TREATMENT OF HEAD AND NECK CANCERS 662 WILLIAM M. MENDENHALL CHARLES E.
RIGGS, JR. NICHOLAS J. CASSISI EPIDEMIOLOGY OF HEAD AND NECK CANCER 662
ANATOMY 662 PATHOLOGY 662 NATURAL HISTORY AND PATTERNS OF SPREAD OF
SQUAMOUS CELL CARCINOMA 663 DIAGNOSTIC EVALUATION 665 STAGING 665
GENERAL PRINCIPLES FOR SELECTION OF TREATMENT 665 MANAGEMENT 666 SECTION
3 REHABILITATION AFTER TREATMENT FOR HEAD AND NECK CANCER MICHAEL A.
CRARY GISELLE D. CARNABY (MANN) GENERAL FUNCTIONAL CONSEQUENCES OF
TREATMENT FOR HEAD AND NECK CANCER 732 TRACHEOSTOMY ISSUES 734
RADIATION THERAPY IMPACT ON SPEECH, VOICE, AND SWALLOWING FUNCTIONS 735
EVALUATION OF SPEECH, VOICE, AND SWALLOWING AFTER HEAD AND NECK CANCER
TREATMENT 736 REHABILITATION OF POSTTREATMENT FUNCTIONAL LIMITATIONS 738
CONCLUSION 742 732 27 CANCER OF THE LUNG. 745 SECTION 1 MOLECULAR
BIOLOGY OF LUNG CANCER 745 YOSHITAKA SEKIDO KWUN M. FONG JOHN D. MINNA
GENETIC AND EPIGENETIC ALTERATIONS IN LUNG CANCERS 745 PROTOONCOGENES
AND GROWTH STIMULATION 746 TUMOR SUPPRESSOR GENES AND GROWTH SUPPRESSION
748 OTHER BIOLOGIC ABNORMALITIES FOR LUNG CANCER DEVELOPMENT MOLECULAR
TOOLS IN THE LUNG CANCER CLINIC 752 749 CONTENTS XLV SECTION 2 NON-SMALL
CELL LUNG CANCER 753 DAVID S. SCHRUMP NASSER K. ALTORKI CLAUDIA L.
HENSCHKE DARRYL CARTER ANDREW T. TURRISI MARTIN E. GUTIERREZ INCIDENCE
753 ETIOLOGY 753 PATHOLOGY 757 MODES OF METASTASIS 762 CLINICAL
MANIFESTATIONS 762 STAGING AND DIAGNOSIS 763 , METHODS TO ESTABLISH
TISSUE DIAGNOSIS 766 LUNG CANCER SCREENING 768 CHEMOPREVENTION 770
OVERVIEW OF INVASIVE LUNG CANCER MANAGEMENT: TREATMENT MODALITIES 770
SPECIFICS OF LUNG CANCER MANAGEMENT 777 SECTION 3 SMALL CELL LUNG CANCER
810 JOHN R. MURREN ANDREW T. TURRISI HARVEY I. PASS EPIDEMIOLOGY AND
ETIOLOGY 810 PATHOLOGY 820 CLINICAL PRESENTATION 822 STAGING EVALUATION
AND PROGNOSTIC FACTORS 822 TREATMENT 825 COMBINATION CHEMOTHERAPY 826
DURATION OF CHEMOTHERAPY 828 APPROACH TO PATIENTS WITH LIMITED DISEASE
829 ROLE OF RADIOTHERAPY IN LIMITED DISEASE 820 ROLE OF SURGERY IN
LIMITED DISEASE 823 APPROACH TO PATIENTS WITH EXTENSIVE DISEASE 826
STRATEGIES TO OPTIMIZE CHEMOTHERAPY RESPONSE 827 HEMATOPOIETIC GROWTH
FACTORS 830 MANAGEMENT OF SMALL CELL LUNG CANCER IN THE ELDERLY AND
INFIRM 832 BIOLOGIC RESPONSE MODIFIERS AND OTHER TREATMENTS 833
TREATMENT AT RELAPSE 834 TREATMENT OUTCOME AND LONG-TERM SURVIVAL 835
EXTRAPULMONARY SMALL CELL CARCINOMA 836 28 NEOPLASMS OF THE MEDIASTINUM
845 ROBERT B. CAMERON PATRICK J. LOEHRER, SR. CHARLES R. THOMAS, JR.
ANATOMY 845 INCIDENCE AND PATHOLOGY 845 DIAGNOSTIC CONSIDERATIONS 846
XHI CONTENTS THYMIC NEOPLASMS 848 GERM CELL TUMORS 852 MESENCHYMAL
TUMORS 855 NEUROGENIC TUMORS 855 PRIMARY CARDIAC MALIGNANCIES 858 29
CANCERS OF THE GASTROINTESTINAL TRACT. 861 SECTION SECTION CANCER OF THE
ESOPHAGUS 861 MITCHELL C. POSNER ARLENE A. FORASTIERE BRUCE D. MINSKY
EPIDEMIOLOGY 862 ETIOLOGIC FACTORS AND PREDISPOSING CONDITIONS 862
APPLIED ANATOMY AND HISTOLOGY 865 MOLECULAR BIOLOGY 867 NATURAL HISTORY
AND PATTERNS OF FAILURE 869 CLINICAL PRESENTATION 869 DIAGNOSTIC STUDIES
AND PRETREATMENT STAGING 870 PATHOLOGIC STAGING 872 TREATMENT 872
STAGE-DIRECTED TREATMENT RECOMMENDATIONS 902 CANCER OF THE STOMACH 909
PETER W. T. PISTERS DAVID P. KELSEN STEVEN M. POWELL JOEL E. TEPPER
EPIDEMIOLOGY AND ETIOLOGY 909 MOLECULAR BIOLOGY 922 PATHOLOGY AND TUMOR
BIOLOGY 924 CLINICAL PRESENTATION AND PRETREATMENT EVALUATION STAGING,
CLASSIFICATION, AND PROGNOSIS 927 TREATMENT OF LOCALIZED DISEASE 922
TREATMENT OF ADVANCED DISEASE (STAGE IV) 934 915 SECTION 3 CANCER OF THE
PANCREAS 945 CHARLES J. YEO THERESA PLUTH YEO RALPH H. HRUBAN SCOTT E.
KERN CHRISTINE A. IACOBUZIO-DONOHUE ANIRBAN MAITRA MICHAEL GOGGINS
MARCIA I. CANTO WELLS MESSERSMITH ROSS A. ABRAMS DANIEL A. LAHERU MANUEL
HIDALGO ELIZABETH M. JAFFEE EPIDEMIOLOGY AND RISK FACTORS 945 CONTENTS
XLVII PATHOLOGY 947 MOLECULAR GENETICS 950 GENE EXPRESSION PROFILING AND
BEYOND 952 SCREENING AND EARLY DETECTION 953 CLINICOPATHOLOGIC STAGING
955 CLINICAL PRESENTATION AND EVALUATION 957 TREATMENT OF POTENTIALLY
RESECTABLE DISEASE 960 TREATMENT OF LOCALLY ADVANCED DISEASE 969
TREATMENT OF METASTATIC AND RECURRENT DISEASE 973 IMMUNOTHERAPY 982
SECTION 4 CANCER OF THE LIVER 986 DAVID L. BARTLETT BRIAN I. CARR J.
WALLIS MARSH EPIDEMIOLOGY 987 ETIOLOGIC FACTORS 988 PATHOLOGY 992
CLINICAL FEATURES 992 STAGING 993 CLINICAL EVALUATION 993 SCREENING OF
HIGH-RISK POPULATIONS 995 CLINICAL MANAGEMENT 996 TREATMENT OF OTHER
PRIMARY LIVER TUMORS 2003 SUMMARY: PRACTICAL GUIDE TO THE MANAGEMENT OF
PATIENTS WITH HEPATOCELLULAR CARCINOMA 2004 SECTION 5 CANCER OF THE
BILIARY TREE 1009 DAVID L. BARTLETT RAMESH K. RAMANATHAN * MELVIN
DEUTSCH CHOLANGIOCARCINOMAS 2009 TUMORS OF THE GALLBLADDER 2022 NEW
ADVANCES FOR TREATMENT OF BILIARY TRACT CANCERS 2032 SECTION 6 CANCER OF
THE SMALL INTESTINE 1035 HERBERT J. ZEH III INCIDENCE 2036 PATHOGENETIC
MECHANISMS IN SMALL INTESTINAL CARCINOGENESIS 2036 GENETIC AND
ENVIRONMENTAL FACTORS THAT PREDISPOSE TO MALIGNANCY ARISING IN THE SMALL
INTESTINE 2037 PRESENTATION AND DIAGNOSIS OF CANCERS ARISING IN THE
SMALL INTESTINE 2038 ADENOCARCINOMA ARISING IN THE SMALL INTESTINE 2040
CARCINOID TUMORS ARISING IN THE SMALL INTESTINE 2042 LYMPHOMA ARISING IN
THE SMALL INTESTINE 2044 MESENCHYMAL TUMORS ARISING IN THE SMALL
INTESTINE 2046 SECTION 7 GASTROINTESTINAL STROMAL TUMORS 1050 GEORGE D.
DEMETRI HISTOPATHOLOGIC FEATURES AND HISTOGENESIS 1050 XLVIII CONTENTS
CLINICAL CONSIDERATIONS 2052 TREATMENT OPTIONS AND MANAGEMENT DECISIONS
IN THE ERA OF MOLECULARLY TARGETED THERAPIES FOR GASTROINTESTINAL
STROMAL TUMOR 2054 SPECIAL CONSIDERATIONS IN GASTROINTESTINAL STROMAL
TUMOR 2058 NEW CHALLENGES AND ALTERNATIVE APPROACHES 2059 SECTION 8
CANCER OF THE COLON 1061 STEVEN K. LIBUTTI LEONARD B. SALTZ ANIL K.
RUSTGI JOEL E. TEPPER EPIDEMIOLOGY 206 2 ETIOLOGY: GENETIC AND
ENVIRONMENTAL RISK FACTORS 2062 BIOLOGY OF COLORECTAL CANCER: CLINICAL
AND MOLECULAR GENETIC RISK FACTORS 2063 ANATOMY OF THE COLON 2065
DIAGNOSIS 2067 SCREENING 2068 STAGING AND PROGNOSIS 2068 APPROACHES TO
SURGICAL RESECTION OF COLON CANCER 2076 POLYPS AND STAGE I COLON CANCER
2080 STAGE II AND STAGE III COLON CANCER 2080 SURGICAL MANAGEMENT OF
STAGE IV DISEASE 2089 MANAGEMENT OF UNRESECTABLE METASTATIC DISEASE 2089
MANAGEMENT OF SYNCHRONOUS PRIMARY AND METASTATIC DISEASE 2202 UNUSUAL
COLORECTAL TUMORS 2202 SECTION 9 CANCER OF THE RECTUM 1110 STEVEN K.
LIBUTTI R , JOEL E. TEPPER LEONARD B. SALTZ ANIL K. RUSTGI ANATOMY 2220
STAGING 2222 SURGERY 2223 STAGE I 2223 COMBINED MODALITY THERAPY (STAGES
II AND III) 2226 CONCURRENT CHEMOTHERAPY 222 9 MANAGEMENT OF
UNRESECTABLE PRIMARY AND LOCALLY ADVANCED DISEASE (T4) 2220 RADIATION
THERAPY TECHNIQUE 2222 RADIATION FIELDS 2222 SECTION 10 CANCER OF THE
ANAL REGION 1125 BERNARD J. CUMMINGS JAFFERA.AJANI CAROL J. SWALLOW
ANATOMY 2225 PATHOLOGY 2226 EPIDEMIOLOGY 2226 RISK FACTORS AND ETIOLOGY
2226 CONTENTS XLIX NATURAL HISTORY 2227 STAGING 2228 PROGNOSTIC FACTORS
2229 ANAL CANAL SQUAMOUS CANCERS 2229 ADENOCARCINOMAS 2235 SMALL CELL
CANCERS 2235 PERIANAL CANCERS 2235 SPECIAL CONSIDERATIONS: PATIENTS WITH
HUMAN IMMUNODEFICIENCY VIRUS INFECTION/ ACQUIRED IMMUNODEFICIENCY
SYNDROME 2236 30 CANCERS OF THE GENITOURINARY SYSTEM 1139 SECTION 1
CANCER OF THE KIDNEY 1139 W. MARSTON LINEHAN SUSAN E. BATES JAMES C.
YANG HISTOLOGIC TYPES OF RENAL CARCINOMA 2239 LOCALIZED RENAL CARCINOMA
2249 METASTATIC RENAL CARCINOMA 2252 SECTION 2 CANCER OF THE BLADDER,
URETER, AND RENAL PELVIS 1168 WILLIAM U. SHIPLEY DONALD S. KAUFMAN W.
SCOTT MCDOUGAL DOUGLAS M. DAHL M. DROR MICHAELSON ANTHONY L. ZIETMAN
EPIDEMIOLOGY 2268 SCREENING AND EARLY DETECTION 2269 PATHOLOGY 2269
MOLECULAR TUMOR MARKERS 2 2 70 CANCER OF THE BLADDER 2 2 72 CANCERS OF
THE URETER AND RENAL PELVIS 2285 SECTION 3 CANCER OF THE PROSTATE 1192
HOWARD I. SCHER STEVEN A. LEIBEL ZVIFUKS CARLOS CORDON-CARDO PETER T.
SCARDINO STATES AND STATE TRANSITIONS 2292 BIOLOGIC CHARACTERIZATION AND
PATHOLOGY 2295 INITIAL UROLOGIC EVALUATION: NO CANCER DIAGNOSIS
LOCALIZED DISEASE 2209 RADIATION THERAPY 2222 EXPECTANT MANAGEMENT 2230
SYSTEMIC THERAPIES 2232 CLINICAL METASTASES: CASTRATE 2242 CONCLUSION
225 0 2203 1 CONTENTS SECTION 4 CANCER OF THE URETHRA AND PENIS 1260
SANJAY RAZDAN LEONARD G. GOMELLA CANCER OF THE MALE URETHRA 2260
CARCINOMA OF THE FEMALE URETHRA 2262 CANCER OF THE PENIS 2262 31 CANCER
OF THE TESTIS 1269 GEORGE J. BOSL DEAN F. BAJORIN JOEL SHEINFELD ROBERT
J.MOTZER R. S. K. CHAGANTI BACKGROUND: INCIDENCE 2269 EPIDEMIOLOGY 2269
INITIAL PRESENTATION AND MANAGEMENT 2270 HISTOLOGY 2270 STAGING 2274
MANAGEMENT OF CLINICAL STAGE I DISEASE 2277 MANAGEMENT OF CLINICAL STAGE
II DISEASE (LOW TUMOR BURDEN) 2282 MANAGEMENT OF STAGE II AND STAGE III
DISEASE (HIGH TUMOR BURDEN) 2282 MANAGEMENT OF RELAPSE AFTER
CHEMOTHERAPY AND REFRACTORY DISEASE 2286 TREATMENT SEQUELAE 2287 MIDLINE
TUMORS OF UNCERTAIN HISTOGENESIS 2289 OTHER TESTICULAR TUMORS 228 9 32
GYNECOLOGIC CANCERS 1295 SECTION 1 CANCER OF THE CERVIX, VAGINA, AND
VULVA 1295 PATRICIA J. EIFEL JONATHAN S. BEREK MAURIE A. MARKMAN
CARCINOMA OF THE CERVIX 2295 CARCINOMA OF THE VAGINA 2320 CARCINOMA OF
THE VULVA 2326 SECTION 2 CANCERS OF THE UTERINE BODY 1341 THOMAS W.
BURKE ARNO J. MUNDT FRANCO M. MUGGIA ENDOMETRIAL CARCINOMA 2342 UTERINE
SARCOMAS 2354 SECTION 3 GESTATIONAL TROPHOBLASTIC DISEASES 1360 FRANCO
M. MUGGIA THOMAS W. BURKE WILLIAM SMALL, JR EPIDEMIOLOGY 2360 CONTENTS
PATHOLOGY AND BIOLOGY 2362 CLINICAL DIAGNOSIS AND HUMAN CHORIONIC
GONADOTROPIN CHORIOCARCINOMA 2362 2362 SECTION 4 OVARIAN CANCER,
PERITONEAL CARCINOMA, AND FALLOPIAN TUBE CARCINOMA 1364 BETH Y. KARLAN
MAURIE A. MARKMAN PATRICIA J. EIFEL OVARIAN CANCER 2364 BORDERLINE
TUMORS 2388 PRIMARY PERITONEAL CARCINOMA 2389 GERM CELL TUMORS OF THE
OVARY 2390 SEX CORD-STROMAL TUMORS 2392 FALLOPIAN TUBE CANCER 2393 33
CANCER OF THE BREAST 1399 1399 SECTION 1 MOLECULAR BIOLOGY OF BREAST
CANCER ROBERT B. DICKSON RICHARD G. PESTELL MARC E. LIPPMAN GENETICS
2399 STEROID AND GROWTH FACTOR PATHWAYS OF CELLULAR REGULATION CELL
CYCLE AND CELL DEATH 2408 PROCESS OF MALIGNANT PROGRESSION 2420
IMPLICATIONS OF MOLECULAR BIOLOGY FOR TUMOR PREVENTION, EARLY DETECTION,
PROGNOSIS, AND RESPONSE TO THERAPY 2422 2402 SECTION 2 MALIGNANT TUMORS
OF THE BREAST 1415 WILLIAM C. WOOD HYMAN B. MUSS LAWRENCE J. SOLIN
OLUFUNMILAYO I. OLOPADE RISK FACTORS FOR BREAST CANCER 2425 DIAGNOSIS
AND BIOPSY 2428 PATHOLOGIC CLASSIFICATION OF TUMOR TYPES 2420 STAGING OF
BREAST CANCER 2422 PROGNOSTIC AND PREDICTIVE FACTORS 2423 ADVISING THE
WOMAN AT HIGH RISK FOR BREAST CANCER 2427 DUCTAL CARCINOMA IN SITU 1429
LOBULAR CARCINOMA IN SITU 1434 PAGET S DISEASE 2434 EARLY-STAGE BREAST
CANCER 2435 LOCALLY ADVANCED AND INFLAMMATORY BREAST CANCER 2450
METASTATIC BREAST CANCER 2453 BREAST CANCER AND PREGNANCY 2462 BILATERAL
BREAST CANCER 2464 MALE BREAST CANCER 2465 NONEPITHELIAL NEOPLASMS 2465
LII CONTENTS LYMPHOMA OF THE BREAST 2466 AXILLARY LYMPH NODE
PRESENTATION 2466 LOCAL AND REGIONAL RECURRENCE 2467 BREAST CANCER IN
THE ELDERLY 2469 SECTION 3 REHABILITATION AFTER TREATMENT FOR CANCER OF
THE BREAST 1478 JEANNE A. PETREK JOSEPH J. DISA DELAYED VERSUS IMMEDIATE
RECONSTRUCTION 2478 PROSTHETIC RECONSTRUCTION 2478 AUTOLOGOUS TISSUE
RECONSTRUCTION 2479 POSTMASTECTOMY AFTER BREAST IRRADIATION 2482
SKIN-SPARING MASTECTOMY WITH IMMEDIATE RECONSTRUCTION 2482 LYMPHEDEMA
2483 34 CANCER OF THE ENDOCRINE SYSTEM 1489 SECTION 1 MOLECULAR BIOLOGY
OF ENDOCRINE TUMORS 1489 TERRY C. LAIRMORE JEFFREY F. MOLEY MULTIPLE
ENDOCRINE NEOPLASIA SYNDROMES 2489 MOLECULAR PATHOGENESIS OF SPORADIC
THYROID NEOPLASMS 2495 GENETIC ABNORMALITIES IN PARATHYROID NEOPLASMS
2497 OTHER GENETIC LOCI IMPLICATED IN FAMILIAL HYPERCALCEMIC SYNDROMES
2498 PARATHYROID CARCINOMA 2499 GENETIC ABNORMALITIES IN ADRENAL
NEOPLASMS 2499 CONCLUSION 2500 SECTION 2 THYROID TUMORS 1502 TOBIAS
CARLING ROBERT UDELSMAN THYROID TUMOR CLASSIFICATION AND STAGING SYSTEMS
2502 EPIDEMIOLOGY AND DEMOGRAPHICS 2503 ETIOLOGY AND RISK FACTORS 2503
EVALUATION OF THE THYROID NODULE 2506 WELL-DIFFERENTIATED THYROID
CARCINOMA 2508 TREATMENT OF WELL- AND INTERMEDIATELY DIFFERENTIATED
THYROID CARCINOMA 2520 POORLY DIFFERENTIATED THYROID CARCINOMA 2524
MEDULLARY THYROID CARCINOMA 2525 THYROID LYMPHOMA 2527 METASTATIC
DISEASE OF THE THYROID 2528 THYROID CARCINOMA IN CHILDREN 2528 SECTION 3
PARATHYROID TUMORS 1521 , DOUGLAS L. FRAKER ! PRIMARY
HYPERPARATHYROIDISM 2522 PATHOLOGY 2522 MOLECULAR GENETICS 2522 CONTENTS
LIII SECTION EPIDEMIOLOGY 2522 CLINICAL PRESENTATION 2524 NATURAL
HISTORY 2524 DIFFERENTIAL DIAGNOSIS 2525 TREATMENT 2525 OUTCOME 2526 4
ADRENAL TUMORS 1528 JEFFREY A. NORTON PATHOLOGY OF THE ADRENAL CORTEX
2528 CLINICAL PRESENTATIONS OF ADRENAL CORTICAL NEOPLASMS 2529 TREATMENT
OF ADRENAL CORTICAL NEOPLASMS PHEOCHROMOCYTOMA 2535 2533 SECTION 3
PANCREATIC ENDOCRINE TUMORS 1540 H. RICHARD ALEXANDER, JR ROBERT T.
JENSEN PATHOGENESIS, PATHOLOGY, TUMOR BIOLOGY 2542 CLINICAL PRESENTATION
AND DIAGNOSIS 254 3 IMAGING AND LOCALIZATION OF PANCREATIC ENDOCRINE
TUMORS 2547 TREATMENT OF RESECTABLE DISEASE 2548 TREATMENT OF METASTATIC
DISEASE 2555 SECTION 6 CARCINOID TUMORS AND THE CARCINOID SYNDROME 1559
ROBERT T. JENSEN GERARD M. DOHERTY PATHOLOGY AND TUMOR HISTOLOGY 2559
MOLECULAR PATHOGENESIS 2562 CLINICAL FEATURES 2562 CARCINOID SYNDROME
2563 TREATMENT OF THE CARCINOID TUMOR 2572 SECTION 7 MULTIPLE ENDOCRINE
NEOPLASMS 1575 GERARD M. DOHERTY ROBERT T. JENSEN MULTIPLE ENDOCRINE
NEOPLASIA TYPE 1 2575 FAMILIAL MEDULLARY THYROID CARCINOMA AND MULTIPLE
ENDOCRINE NEOPLASIA TYPES 2A AND 2B 2578 35 SARCOMAS OF THE SOFT TISSUES
AND BONE 1581 SECTION 1 SOFT TISSUE SARCOMA MURRAY F. BRENNAN SAMUEL
SINGER ROBERT G. MAKI BRIAN O SULLIVAN INCIDENCE 2582 1581 LIV CONTENTS
ETIOLOGY AND GENETICS 2582 DISTRIBUTION 2584 PATHOLOGIC CLASSIFICATION
2584 GRADING OF SARCOMA 2587 DIFFERENTIAL DIAGNOSIS 2588
CLINICOPATHOLOGIC FEATURES OF SPECIFIC TYPES OF BENIGN AND MALIGNANT
SOFT TISSUE TUMORS 2589 CLINICAL PRESENTATION 2597 DIFFERENTIAL
DIAGNOSIS 2597 MANAGEMENT OF EXTREMITY AND SUPERFICIAL TRUNCAL SOFT
TISSUE SARCOMA 2 602 RADIATION THERAPY 2603 ADJUVANT BRACHYTHERAPY 2608
SPECIAL CONSIDERATIONS 2609 DEFINITIVE RADIATION 2620 ADJUVANT
CHEMOTHERAPY 2622 PREOPERATIVE CHEMOTHERAPY 2626 INTRAARTERIAL
CHEMOTHERAPY 2627 HYPERTHERMIA AND LIMB PERFUSION 2627 SPECIAL FEATURES
OF THE MANAGEMENT OF SARCOMAS OF NONEXTREMITY SITES 2628 SERIOUS
COMPLICATIONS OF PRIMARY TREATMENT 2620 PROGNOSTIC FACTORS 2622 QUALITY
OF LIFE AND FUNCTIONAL OUTCOME 2623 TREATMENT OF LOCAL RECURRENCE 2623
MANAGEMENT OF ADVANCED DISEASE 2624 RESECTION OF METASTATIC DISEASE 2624
SYSTEMIC THERAPY FOR ADVANCED DISEASE 2624 RESPONSE BY HISTOLOGIC
SUBTYPE AND SITE 2629 RECOMMENDATIONS FOR PATIENTS WITH ADVANCED
DISEASE 2632 FUTURE DIRECTIONS 2632 SECTION 2 SARCOMAS OF BONE 1638
MARTIN M. MALAWER LEE J. HELMAN BRIAN O SULLIVAN CLASSIFICATION AND
TYPES OF BONE TUMOR 2638 RADIOGRAPHIC EVALUATION AND DIAGNOSIS 2639
NATURAL HISTORY 2640 STAGING BONE TUMORS 2642 PREOPERATIVE EVALUATION
2642 BIOPSY TECHNIQUE AND TIMING 2644 RESTAGING AFTER INDUCTION
(PREOPERATIVE) CHEMOTHERAPY 2645 SURGICAL MANAGEMENT OF SKELETAL TUMORS
2646 PRINCIPLES AND TECHNIQUES OF LIMB-SPARING SURGERY 2647 LIMB-SPARING
SURGERY AND PERIOPERATIVE PAIN MANAGEMENT 2648 AMPUTATIONS 2652
CRYOSURGERY 2652 CHEMOTHERAPY FOR BONE SARCOMAS 2652 RADIOTHERAPY FOR
BONE TUMORS 2658 MALIGNANT BONE TUMORS 2660 CONTENTS LV 36 BENIGN AND
MALIGNANT MESOTHEIIOMA 1687 HARVEY I. PASS NICHOLAS J. VOGELZANG STEPHEN
M. HAHN MICHELE CARBONE MECHANISM OF ASBESTOS-INDUCED ONCOGENESIS 2687
MECHANISM OF ASBESTOS PATHOGENICITY 2688 OVERVIEW OF MOLECULAR
MECHANISMS IN MESOTHEIIOMA 2688 SIMIAN VIRUS 40 2690 RADIATION AND
MESOTHEIIOMA 2690 GENETIC PREDISPOSITION TO MESOTHEIIOMA 2690 PATHOLOGY
OF MESOTHEIIOMA 2692 SOLITARY FIBROUS TUMORS OF PLEURA 2693 CLINICAL
PRESENTATION OF MALIGNANT PLEURAL MESOTHEIIOMA 2693 DIAGNOSTIC APPROACH
2698 NATURAL HISTORY 2699 PROGNOSTIC INDICATORS 2699 STAGING 2700
TREATMENT 2700 MALIGNANT PERITONEAL MESOTHEIIOMA 2720 MALIGNANT
MESOTHEIIOMA OF THE TUNICA VAGINALIS TESTIS 2 722 MALIGNANT MESOTHEIIOMA
OF THE PERICARDIUM 2722 37 CANCER OF THE SKIN 171 7 SUMAIRA Z. AASI
DAVID J. LEFFELL DIAGNOSIS 2727 GENERAL APPROACH TO MANAGEMENT OF SKIN
CANCER 2728 PRECANCEROUS LESIONS 2723 CARCINOMA METASTATIC TO SKIN 2742
CONCLUSION 2742 38 MELANOMA 1745 SECTION 1 MOLECULAR BIOLOGY OF
CUTANEOUS MELANOMA 1745 ZHAO-JUN LIU MEENHARD HERLYN ETIOLOGY OF
MELANOMA 2745 GENETICS OF MELANOMA 2746 BIOLOGIC BASIS OF MELANOMA
DEVELOPMENT AND PROGRESSION 2749 SECTION 2 CUTANEOUS MELANOMA 1754
CHARLES M. BALCH ! MICHAEL B. ATKINS ARTHUR J. SOBER EPIDEMIOLOGY 2754
HI CONTENTS ANATOMIC DISTRIBUTION 2755 RISK FACTORS 2756 PREVENTION AND
SCREENING 2757 DIAGNOSIS OF MELANOMA 2759 PROGNOSTIC FACTORS 2760 NEW
STAGING SYSTEM FOR MELANOMA 2765 BIOPSY 2769 SURGICAL TREATMENT OF
PRIMARY MELANOMA (STAGES I TO III) 2769 LOCAL RECURRENCES 2 774
MANAGEMENT OF REGIONAL NODES*LYMPHADENECTOMY (STAGE III) 2774
RADIOTHERAPY FOR REGIONAL METASTASES (STAGE III) 2778 REGIONAL RELAPSES
2779 ADJUVANT SYSTEMIC THERAPY (STAGES II AND III) 2 780 FOLLOW-UP OF
MELANOMA PATIENTS (STAGES I TO III) 2 786 DIAGNOSIS OF STAGE IV MELANOMA
2786 SURGERY AND IRRADIATION FOR DISTANT METASTASES (STAGE IV) 2787
SYSTEMIC TREATMENT OF STAGE IV MELANOMA 2792 SECTION 3 INTRAOCULAR
MELANOMA 1809 ROBERT B. AVERY MINESH P. MEHTA RICHARD M. AUCHTER DANIEL
M, ALBERT EPIDEMIOLOGY 2809 MORTALITY 2820 NATURAL HISTORY 2820 ETIOLOGY
AND PATHOGENESIS 2822 HISTOPATHOLOGY 2822 DIAGNOSIS 2823 PROGNOSTIC
ASSESSMENT 2825 THERAPEUTIC APPROACHES 2826 RADIATION THERAPY 2827
MANAGEMENT 2823 FUTURE DIRECTIONS 2824 39 NEOPLASMS OF THE CENTRAL
NERVOUS SYSTEM 1827 SECTION 1 MOLECULAR BIOLOGY OF CENTRAL NERVOUS
SYSTEM NEOPLASMS 1827 DAVID N. LOUIS WEBSTER K. CAVENEE DIFFUSE,
FIBRILLARY ASTROCYTOMAS 2827 OTHER GLIOMAS 2829 MEDULLOBLASTOMAS 2832
MENINGIOMAS 2832 PERIPHERAL NERVE TUMORS 2832 ! MISCELLANEOUS TUMORS
2832 NEUROLOGIC TUMOR SYNDROMES 2832 X CONCLUSION 2833 CONTENTS IVII
SECTION 2 NEOPLASMS OF THE CENTRAL NERVOUS SYSTEM 1834 HOWARD A. FINE
FRED G. BARKER II JAMES M. MARKERT JAY S. LOEFFLER GENERAL
CONSIDERATIONS 2834 ANATOMIC AND CLINICAL CONSIDERATIONS 2836
NEURODIAGNOSTIC TESTS 2838 SURGERY 2842 RADIATION THERAPY 2843
CHEMOTHERAPY 2845 CEREBRAL ASTROCYTOMAS 2847 BRAINSTEM GLIOMAS 2854
CEREBELLAR ASTROCYTOMAS 2856 OPTIC, CHIASMAL, AND HYPOTHALAMIC GLIOMAS
2856 OLIGODENDROGLIOMAS 2858 EPENDYMOMAS 2860 MENINGIOMAS 2862 PRIMITIVE
NEUROEPITHELIAL TUMORS 2865 MEDULLOBLASTOMAS 2865 PINEAL REGION TUMORS
2869 PITUITARY ADENOMAS 2872 CRANIOPHARYNGIOMAS 2873 ACOUSTIC NEUROMAS
(VESTIBULAR SCHWANNOMAS) 2874 GLOMUS JUGULARE TUMORS 2875 CHORDOMAS AND
CHONDROSARCOMAS 2876 HEMANGIOBLASTOMAS 2877 CHOROID PLEXUS PAPILLOMAS
AND CARCINOMAS 2879 SPINAL AXIS TUMORS 2880 40 CANCERS OFCHIIDHOOD 1889
SECTION 1 MOLECULAR BIOLOGY OF CHILDHOOD CANCERS 1889 LEE J. HELMAN
DAVID MALKIN TUMOR SUPPRESSOR GENES 2890 RETINOBLASTOMA: THE PARADIGM
2890 WILMS TUMOR: THREE DISTINCT LOCI 2892 NEUROFIBROMATOSES 2892
NEUROBLASTOMA 2892 EWING S SARCOMA FAMILY OF TUMORS 2893
RHABDOMYOSARCOMA 2893 HEREDITARY SYNDROMES ASSOCIATED WITH TUMORS OF
CHILDHOOD 2894 I PREDICTIVE TESTING FOR GERMLINE MUTATIONS AND CHILDHOOD
CANCERS . 2895 MOLECULAR THERAPEUTICS 2895 IVIII CONTENTS SECTION 2
SOLID TUMORS OF CHILDHOOD 1898 DAVID H. EBB DANIEL M. GREEN ROBERT C.
SHAMBERGER NANCY J. TARBELL EPIDEMIOLOGY 2898 MANAGEMENT OF CHILDHOOD
CANCER 2898 WILMS TUMOR 2898 FAVORABLE HISTOLOGY WILMS TUMOR 2903
NEUROBLASTOMA 2904 RETINOBLASTOMA 290 9 ADVANCED UNILATERAL DISEASE 2922
LIMITED UNILATERAL OR LIMITED BILATERAL DISEASE 2922 BILATERAL DISEASE
2922 CHEMOTHERAPY 2922 RHABDOMYOSARCOMA 2922 EWING S SARCOMA AND
PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR 2929 PRIMARY HEPATIC TUMORS
2923 GERM CELL TUMORS 2926 CLINICAL PRESENTATION AND TREATMENT BY
ANATOMIC SITE 2928 41 LYMPHOMAS SECTION 1 LEUKEMIAS AND LYMPHOMAS OF
CHILDHOOD 1939 HOWARD J. WEINSTEIN NANCY J. TARBELL LEUKEMIAS 2939
NON-HODGKIN S LYMPHOMA 2948 HODGKIN S DISEASE 2953 1939 SECTION 2
NON-HODGKIN S LYMPHOMAS 1957 RICHARD I. FISHER PETER M. MAUCH NANCY LEE
HARRIS JONATHAN W. FRIEDBERG EPIDEMIOLOGY 2957 ETIOLOGY 2958 BIOLOGIC
BACKGROUND FOR CLASSIFICATION OF LYMPHOID NEOPLASMS 2959 PRINCIPLES OF
THE REVISED EUROPEAN-AMERICAN CLASSIFICATION OF LYMPHOID NEOPLASMS/
WORLD HEALTH ORGANIZATION CLASSIFICATION OF LYMPHOID NEOPLASMS 2967
PRINCIPLES OF MANAGEMENT OF NON-HODGKIN S LYMPHOMA 2969 SPECIFIC DISEASE
ENTITIES 2972 SPECIAL CLINICAL SITUATIONS 2990 CONTENTS LIX SECTION 3
CUTANEOUS T-CELL LYMPHOMAS 1998 LYNN D. WILSON GLENN W. JONES MICHAEL
GIRARDI RICHARD L. EDELSON PETER W.HEALD ;* PATHOBIOLOGY 2998
EPIDEMIOLOGY 2998 ETIOLOGY 2998 CLINICAL PRESENTATION 2999 APPROACH TO
THE PATIENT WITH MYCOSIS FUNGOIDES 2000 PATIENT EVALUATION 2002
PRINCIPLES OF THERAPY 2003 OTHER CLINICAL MANAGEMENT ISSUES 2020 SECTION
4 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA 2012 LISA M. DEANGELIS JOACHIM
YAHALOM CLINICAL FEATURES 2022 DIAGNOSTIC TESTS 2023 PATHOLOGY 2023
MANAGEMENT AND THERAPY 2024 IMMUNOLOGICALLY NORMAL PATIENTS 2025
IMMUNOCOMPROMISED PATIENTS 2029 SECTION 5 HODGKIN S LYMPHOMA 2020 VOLKER
DIEHL NANCY LEE HARRIS PETER M. MAUCH HISTORY 2020 ETIOLOGY AND
EPIDEMIOLOGY 2022 BIOLOGY AND CELL OF ORIGIN 2022 PATHOLOGY 2026
DIAGNOSIS AND STAGING 2032 CLINICAL PRESENTATION 2034 TREATMENT METHODS
2035 CHOICE OF TREATMENT 2038 SPECIAL CASES 2059 SEQUELAE 2062 QUALITY
OF LIFE 2064 NEW DRUGS FOR TREATMENT OF HODGKIN S LYMPHOMA 2064
IMMUNOTHERAPY 2065 GENE THERAPY 2068 42 ACUTE LEUKEMIAS 2077 SECTION 1
MOLECULAR BIOLOGY OF ACUTE LEUKEMIAS 2077 I D. GARY GILLILAND GLEN DAVID
RAFFEL LEUKEMIC STEM CELL 2077 IX CONTENTS RECURRING CHROMOSOMAL
ABNORMALITIES IN ACUTE LEUKEMIA 2078 DELETIONS AND NUMERIC ABNORMALITIES
IN ACUTE LEUKEMIAS 2083 CHROMOSOMAL TRANSLOCATIONS THAT RESULT IN
OVEREXPRESSION OF OTHERWISE NORMAL GENES 2084 POINT MUTATIONS IN ACUTE
LEUKEMIA 2084 MUTATIONAL COMPLEMENTATION GROUPS IN ACUTE LEUKEMIAS 2085
CONCLUSION 2086 SECTION 2 MANAGEMENT OF ACUTE LEUKEMIAS 2088 DAVID A.
SCHEINBERG PETER G. MASLAK MARK A. WEISS EPIDEMIOLOGY AND ETIOLOGY 2088
BIOLOGY OF ACUTE LEUKEMIAS 2090 DIAGNOSIS AND CLASSIFICATION OF ACUTE
LEUKEMIAS 2092 PRINCIPLES OF CLINICAL MANAGEMENT OF ACUTE MYELOGENOUS
LEUKEMIA 2098 TREATMENT OF NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA
2200 INDUCTION 2200 TREATMENT OF RELAPSED ACUTE MYELOGENOUS LEUKEMIA
2206 CONCLUSION 2225 43 CHRONIC LEUKEMIAS. 2121 SECTION 1 CHRONIC
MYELOGENOUS LEUKEMIA 2121 BRIAN J. DRUKER STEPHANIE J. LEE EPIDEMIOLOGY
2222 PATHOGENESIS 2222 DIAGNOSIS AND CLINICAL COURSE 2223 TREATMENT OF
CHRONIC-PHASE DISEASE 2224 ADVANCED-PHASE DISEASE 2230 FUTURE DIRECTIONS
2232 SECTION 2 CHRONIC LYMPHOID LEUKEMIAS 2133 SUSAN O BRIEN MICHAEL J.
KEATING MOLECULAR BIOLOGY 2233 IMMUNE ABNORMALITIES 2235 DIAGNOSIS 2235
CLINICAL MANIFESTATIONS 2235 TREATMENT AND RESPONSE CRITERIA 2238
BIOLOGIC THERAPIES 2240 SECOND MALIGNANCIES AND TRANSFORMATION 2242
PROLYMPHOCYTIC LEUKEMIA 2242 LARGE GRANULAR LYMPHOCYTE LEUKEMIA 2242
HAIRY CELL LEUKEMIA 2242 CONTENTS LXI SECTION 3 MYELODYSPLASTIC
SYNDROMES 2144 STEFAN FADERL HAGOP M. KANTARJIAN INCIDENCE AND
EPIDEMIOLOGY 2244 ETIOLOGY 2244 CLASSIFICATION AND PROGNOSTIC FACTORS
2245 BIOLOGY AND PATHOPHYSIOLOGY OF MYELODYSPLASTIC SYNDROMES 2246
CLINICAL MANIFESTATIONS 2248 LABORATORY FEATURES 2248 DIFFERENTIAL
DIAGNOSIS 2248 SUBTYPES OF MYELODYSPLASTIC SYNDROMES 2248 THERAPY OF
MYELODYSPLASTIC SYNDROMES 2249 CONCLUSION 2253 44 PLASMA CELL NEOPLASMS
2155 NIKHIL C. MUNSHI KENNETH C. ANDERSON HISTORY 2255 EPIDEMIOLOGY 2256
ETIOLOGY: ENVIRONMENTAL EXPOSURE 2256 PATHOGENESIS 2257 CLINICAL
MANIFESTATIONS 2263 DIAGNOSIS 2265 DIFFERENTIAL DIAGNOSIS 2268
PROGNOSTIC VARIABLES 2 2 70 TREATMENT 2272 WALDENSTROM S
MACROGLOBULINEMIA 2282 45 PARANEOPLASTIC SYNDROMES 2189 SUSANNE M.
ARNOLD FRANK S. LIEBERMAN KENNETH A. FOON ENDOCRINOLOGIC MANIFESTATIONS
OF CANCER 2289 HEMATOLOGIC MANIFESTATIONS OF CANCER 2293
GASTROINTESTINAL MANIFESTATIONS OF CANCER 2296 RENAL MANIFESTATIONS OF
NONRENAL CANCER 2297 CUTANEOUS MANIFESTATIONS OF CANCER 2297 NEUROLOGIC
MANIFESTATIONS OF CANCER 2200 MISCELLANEOUS PARANEOPLASTIC SYNDROMES
2207 46 CANCER OF UNKNOWN PRIMARY SITE 2213 F. ANTHONY GRECO JOHN D.
HAINSWORTH POORLY DIFFERENTIATED NEOPLASMS OF UNKNOWN PRIMARY SITE 2224
LXII CONTENTS POORLY DIFFERENTIATED CARCINOMA (WITH OR WITHOUT FEATURES
OF ADENOCARCINOMA) OF UNKNOWN PRIMARY SITE 2226 NEUROENDOCRINE CARCINOMA
OF UNKNOWN PRIMARY SITE 2222 ADENOCARCINOMA OF UNKNOWN PRIMARY SITE 2222
SQUAMOUS CARCINOMA OF UNKNOWN PRIMARY SITE 2225 CHEMOTHERAPY FOR
METASTATIC CARCINOMA OF UNKNOWN PRIMARY SITE 2226 SPECIAL ISSUES IN
CARCINOMA OF UNKNOWN PRIMARY SITE 2229 CONCLUSION 2232 47 PERITONEAL
CARCINOMATOSIS JAMES F. PINGPANK, JR. PATHOPHYSIOLOGY 2237 DIAGNOSTIC
EVALUATION 2238 HISTOLOGIC SUBTYPES 2238 TREATMENT 2242 2237 48
IMMUNOSUPPRESSION-RELATED MALIGNANCIES. 2247 SECTION 1 AIDS-RELATED
MALIGNANCIES 2247 ROBERT YARCHOAN RICHARD F. LITTLE KAPOSI S SARCOMA
2247 AIDS-ASSOCIATED LYMPHOMAS 2253 PRIMARY CENTRAL NERVOUS SYSTEM
LYMPHOMA IN AIDS 2258 HODGKIN S DISEASE 2259 ANOGENITAL CANCERS IN HUMAN
IMMUNODEFICIENCY VIRUS INFECTION 2259 FUTURE DIRECTIONS 2260 SECTION 2
TRANSPLANTATION-RELATED MALIGNANCIES 2263 STANLEY R. RIDDELL IMMUNE
SURVEILLANCE AND TUMOR DEVELOPMENT 2263 HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS 2263 ORGAN TRANSPLANT RECIPIENTS 2267 49 ONCOLOGLC
EMERGENCIES SECTION 1 2273 SUPERIOR VENA CAVA SYNDROME JOACHIM YAHALOM
ANATOMY AND PATHOPHYSIOLOGY 2273 ETIOLOGY AND NATURAL HISTORY 2273
DIAGNOSTIC PROCEDURES 2275 MANAGEMENT 2276 2273 CONTENTS LXIII TREATMENT
2277 RECOMMENDATIONS 2279 SECTION 2 INCREASED INTRACRANIAL PRESSURE 2281
JOACHIM M. BAEHRING PATHOPHYSIOLOGIC CONSIDERATIONS 2282 EPIDEMIOLOGY
AND PATHOGENESIS 2282 CLINICAL PRESENTATION 2282 DIAGNOSIS 2284
TREATMENT 2286 SECTION 3 SPINAL CORD COMPRESSION 2287 JOACHIM M.
BAEHRING EPIDEMIOLOGY 2287 PATHOPHYSIOLOGY 2287 CLINICAL PRESENTATION
2289 DIFFERENTIAL DIAGNOSIS 2290 DIAGNOSIS 2290 TREATMENT 2292 PROGNOSIS
2292 CONCLUSION 2292 SECTION 4 METABOLIC EMERGENCIES 2292 ANTONIO TITO
FOJO TUMOR LYSIS SYNDROME 2292 HYPERURICEMIA 2294 CANCER AND
HYPONATREMIA 2295 LACTIC ACIDOSIS AND CANCER 2296 HYPERCALCEMIA AND
CANCER 2297 CANCER-RELATED HEMOLYTIC-UREMIC SYNDROME 2299 SECTION 5
UROLOGIC EMERGENCIES 2301 JONATHAN A. COLEMAN MCCLELLAN M. WALTHER
URINARY TRACT INFECTION 2302 CYSTITIS 2302 BLADDER HEMORRHAGE 2304
URINARY OBSTRUCTION 2305 PRIAPISM 2307 PARAPHIMOSIS 2307 50 SPECIALIZED
TECHNIQUES IN CANCER MANAGEMENT 2309 SECTION 1 VASCULAR ACCESS AND
SPECIALIZED TECHNIQUES OF DRUG DELIVERY 2309 JAMES F. PINGPANK, JR.
CATHETER TYPES 2309 LXIV CONTENTS CATHETER SELECTION 2322 INSERTION
TECHNIQUES 2322 CATHETER-RELATED COMPLICATIONS 2324 SECTION 2 ISOLATION
PERFUSION 2316 H. RICHARD ALEXANDER, JR. PRINCIPLES OF ISOLATION
PERFUSION 2326 RESULTS OF ISOLATION PERFUSION 2328 CURRENT STATUS OF
ISOLATED LIMB PERFUSION 2329 CURRENT STATUS OF ISOLATED HEPATIC
PERFUSION 2322 STATUS OF ISOLATION PERFUSION OF OTHER SITES 2322
VARIATIONS OF ISOLATION PERFUSION TECHNIQUES 2322 CONCLUSION 2322 51
TREATMENT OF METASTATIC CANCER 2323 SECTION 1 METASTATIC BRAIN CANCER
2323 DAVID A. LARSON JAMES L. RUBENSTEIN MICHAEL W. MCDERMOTT BRAIN
METASTASES 2323 CARCINOMATOUS MENINGITIS 2333 SECTION 2 METASTATIC
CANCER TO THE LUNG 2337 MICHAEL R. JOHNSTON MARC DE PERROT BIOLOGY 2337
DIAGNOSIS 2337 TREATMENT 2339 RESULTS 2346 SECTION 3 METASTATIC CANCER
TO THE LIVER 2352 H. RICHARD ALEXANDER, JR NANCY E. KEMENY THEODORE S.
LAWRENCE NATURAL HISTORY OF LIVER METASTASES 2353 IMAGING OF HEPATIC
METASTASES 2354 RESECTION: TECHNICAL CONSIDERATIONS 2354 RESULTS OF
HEPATIC RESECTION FOR COLORECTAL CANCER 2355 RESULTS OF RESECTION FOR
NONCOLORECTAL CANCERS 2355 HEPATIC ARTERIAL CHEMOTHERAPY 2356 TOXICITY
OF HEPATIC ARTERIAL INFUSION THERAPY WITH FLOXURIDINE 2358 OTHER AGENTS
USED WITH HEPATIC ARTERIAL INFUSION 2359 ADJUVANT THERAPY AFTER
RESECTION OF COLORECTAL LIVER METASTASES 2359 NEOADJUVANT CHEMOTHERAPY
2360 OTHER LIVER TUMORS 2360 CONTENTS LXV HEPATIC ARTERY INFUSION WITH
HEPATIC VENOUS FILTRATION 2360 ISOLATED HEPATIC PERFUSION 2362
CHEMOEMBOLIZATION FOR METASTATIC CANCER TO THE LIVER 2362 LOCAL ABLATIVE
THERAPY 2362 CRYOTHERAPY 2363 RADIOFREQUENCY ABLATION 2363 OTHER
ABLATIVE TECHNIQUES 2364 RESULTS OF WHOLE LIVER IRRADIATION
CHEMOTHERAPY 2365 CONCLUSION 2366 SECTION 4 METASTATIC CANCER TO THE
BONE MARK W. MANOSO JOHN H. HEALEY PRESENTATION 2368 PATHOPHYSIOLOGY
2369 DIAGNOSTIC EVALUATION 2369 IMAGING OF BONE LESIONS 2370 THERAPEUTIC
GOALS 2372 THERAPEUTIC MODALITIES 2372 2368 SECTION 5 MALIGNANT PLEURAL
AND PERICARDIAL EFFUSIONS DAO M. NGUYEN DAVID S. SCHRUMP MALIGNANT
PLEURAL EFFUSION 2382 MALIGNANT PERICARDIAL EFFUSION 2387 SECTION 6
MALIGNANT ASCITES 2392 RICHARD B. HOSTETTER FRANCESCO M. MARINCOLA
DOUGLAS J. SCHWARTZENTRUBER DIAGNOSIS AND WORKUP 2392 TREATMENT OF
MALIGNANT ASCITES 2393 CONCLUSION 2396 2381 52 HEMATOPOIETIC THERAPY
SECTION 1 TRANSFUSION THERAPY 2399 2399 YANYUN WU PETER L. PERROTTA
EDWARD L. SNYDER BLOOD COMPONENT THERAPY 2400 TRANSFUSION REACTIONS AND
COMPLICATIONS 2406 TRANSFUSION-TRANSMITTED DISEASE 2409 USE OF SPECIAL
BLOOD PRODUCTS IN ONCOLOGY PATIENTS 2420 APHERESIS 2422 EFFECT OF GROWTH
FACTORS ON TRANSFUSION MEDICINE 2422 BLOOD SUBSTITUTES 2422 LXVI
CONTENTS SECTION 2 AUTOLOGOUS STEM CELL TRANSPLANTATION 2414 DENNIS L.
COOPER STUART SEROPIAN HISTORY 2425 STEM CELL MOBILIZATION 2425
INADEQUATE MOBILIZATION OF STEM CELLS 2426 TUMOR CONTAMINATION 2428
PRACTICAL CONSIDERATIONS FOR THE POTENTIAL AUTOLOGOUS STEM CELL PATIENT
2429 HIGH-DOSE THERAPY REGIMENS: NEW DIRECTIONS 2429 LATE TOXICITY:
MYELODYSPLASIA AND SECONDARY LEUKEMIA 2422 FUTURE DIRECTIONS 2422
SECTION 3 AHOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 2423 RICHARD
W. CHILDS CONDITIONING REGIMENS 2424 GRAFT-VERSUS-LEUKEMIA EFFECT 2425
MECHANISMS OF GRAFT-VERSUS-LEUKEMIA EFFECT 2427 COMPLICATIONS OF
AHOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION 2427 EPSTEIN-BARR
VIRUS LYMPHOPROLIFERATIVE DISORDER 2429 SOURCES OF AHOGENEIC
HEMATOPOIETIC STEM CELLS 2432 RESULTS OF CONVENTIONAL AHOGENEIC
TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES 2434 NONMYELOABLATIVE
AHOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION 2435 FUTURE PROSPECTS 2439
SECTION 4 HEMATOPOIETIC GROWTH FACTORS 2442 JENNIFER L. HOLTER HOWARD
OZER OVERVIEW OF HEMATOPOIESIS AND HEMATOPOIETIC GROWTH FACTORS 2442
CLINICAL USE OF RECOMBINANT ERYTHROPOIETIN IN CANCER THERAPY 2448 ANEMIA
RELATED TO MYELOPROLIF ERATIVE DISORDERS 2450 PREDICTORS OF RECOMBINANT
ERYTHROPOIETIN THERAPY RESPONSE 2452 CLINICAL USE OF RECOMBINANT
GRANULOCYTE COLONY-STIMULATING FACTORS IN CANCER THERAPY 2452 CLINICAL
USE OF RECOMBINANT INTERLEUKIN-11 IN CANCER THERAPY 2455 HEMATOPOIETIC
GROWTH FACTORS IN DEVELOPMENT 2456 CONCLUSION 2456 53 INFECTIONS IN THE
CANCER PATIENT 2461 BRAHM H. SEGAL THOMAS J.WALSH JUAN C. GEA-BANACLOCHE
STEVEN M. HOLLAND FACTORS PREDISPOSING CANCER PATIENTS TO INFECTION 2462
BACTERIAL INFECTIONS IN CANCER PATIENTS 2465 FUNGAL INFECTIONS 2469
VIRAL INFECTIONS 2477 PARASITIC INFECTIONS 2484 CONTENTS IXVI I
NEUTROPENIC FEVER 2486 SYNDROMES 2496 IMMUNE AUGMENTATION STRATEGIES
2506 54 ADVERSE EFFECTS OF TREATMENT 2515 SECTION 1 NAUSEA AND VOMITING
2515 ANN M. BERGER REBECCA A. CLARK-SNOW NATURE OF THE PROBLEM 2525
PATHOPHYSIOLOGY OF NAUSEA AND VOMITING 2525 EMETIC SYNDROMES 2527
CONTROL OF EMESIS AND RISK FACTORS 2528 ANTIEMETIC AGENTS 2529 TREATMENT
OPTIONS BASED ON EMESIS CATEGORY 2520 NEW AGENTS 2520 RADIATION-INDUCED
NAUSEA AND VOMITING 2522 NAUSEA AND VOMITING SECONDARY TO COMORBID
CONDITIONS 2522 IMPROVING ANTIEMETIC CONTROL 2522 SECTION 2 ORAL
COMPLICATIONS 2523 ANN M. BERGER JANE M. FALL-DICKSON ORAL COMPLICATIONS
2523 SEQUELAE OF ORAL COMPLICATIONS 2525 STRATEGIES FOR PREVENTION AND
TREATMENT OF ORAL COMPLICATIONS 2526 FUTURE RESEARCH DIRECTIONS 2533
CONCLUSION 2533 SECTION 3 PULMONARY TOXICITY 2535 DIANE E. STOVER ROBERT
J. KANER RADIATION-INDUCED PULMONARY TOXICITY 2535 RADIATION-RELATED
BRONCHIOLITIS OBLITERANS WITH ORGANIZING PNEUMONIA 2538
CHEMOTHERAPY-INDUCED PULMONARY TOXICITY 2539 SECTION 4 CARDIAC TOXICITY
2545 JOACHIM YAHALOM CAROL S. PORTLOCK ANTHRACYCLINES 2545 MITOXANTRONE
2547 CYCLOPHOSPHAMIDE 2547 IFOSFAMIDE 2547 TAXANES 2547 TRASTUZUMAB 2548
FLUOROPYRIMIDINES 2549 RADIATION-INDUCED HEART DISEASE 2549 CONCLUSION
2553 IXVILI CONTENTS SECTION 5 HAIR LOSS 2556 ANN M. BERGER JOYSON
KARAKUNNEL ANATOMY AND PHYSIOLOGY 2556 CLASSIFICATION 2556 STAGING 2557
DIAGNOSIS 2557 TREATMENT 2557 CONCLUSION 2559 SECTION 6 GONADAL
DYSFUNCTION 2560 MARVIN L. MEISTRICH RENA VASSILOPOULOU-SELLIN LARRY I.
LIPSHULTZ EFFECTS OF CYTOTOXIC AGENTS ON ADULT MEN 2560 EFFECTS OF
CYTOTOXIC AGENTS ON ADULT WOMEN 2563 EFFECTS OF CYTOTOXIC AGENTS ON
CHILDREN 2566 GONADAL DYSFUNCTION AFTER CRANIAL IRRADIATION 2566
PRESERVATION OF FERTILITY, HORMONE LEVELS, AND SEXUAL FUNCTION 2567
PREVENTION AND MANAGEMENT OF ERECTILE AND EJACULATORY DYSFUNCTION 2570
GENETIC CONCERNS 2572 COUNSELING 2572 SECTION 7 SECOND CANCERS 2575
FLORA E. VAN LEEUWEN LOIS B. TRAVIS METHODS TO ASSESS SECOND CANCER RISK
2575 CARCINOGENICITY OF INDIVIDUAL TREATMENT MODALITIES 2576 RISK OF
SECOND MALIGNANCY IN PATIENTS WITH SELECTED PRIMARY CANCERS CONCLUSION
2598 8 MISCELLANEOUS TOXICITIES 2602 RAYMOND B. WEISS NEUROTOXICITY 2603
NEPHROTOXICITY 2607 HEPATOTOXICITY 2620 HYPERSENSITIVITY REACTIONS 2622
VASCULAR TOXICITY 2622 2580 SECTION 55 SUPPORTIVE CARE AND QUALITY OF
LIFE SECTION 1 MANAGEMENT OF CANCER PAIN 2615 KATHLEEN M. FOLEY
EPIDEMIOLOGY 2625 BARRIERS TO CANCER PAIN MANAGEMENT 262 6 DEFINITION OF
PAIN 2627 ANATOMY AND PHYSIOLOGY OF PAIN 2627 TYPES OF PAIN 2628
TEMPORAL ASPECTS OF PAIN 2629 2615 CONTENTS LXLX INTENSITY OF PAIN 2629
MEASUREMENT OF PAIN 2629 CLASSIFICATION OF PATIENTS WITH CANCER PAIN
2622 COMMON PAIN SYNDROMES 2624 CLINICAL ASSESSMENT OF PAIN 2624
MANAGEMENT OF CANCER PAIN 2627 ANALGESIC DRUG THERAPY 2627 CLASSES OF
DRUGS 2630 PSYCHOLOGICAL APPROACHES 2639 ANESTHETIC AND NEUROSURGICAL
APPROACHES 2639 PHYSIATRIC APPROACHES 2645 SEDATION IN THE IMMINENTLY
DYING 2645 ALGORITHM FOR CANCER PAIN MANAGEMENT 2646 FUTURE DIRECTIONS
2646 SECTION 2 NUTRITIONAL SUPPORT 2649 J. STANLEY SMITH DAVID
FRANKENFIELD WILEY W. SOUBA DYSGEUSIA 2649 WEIGHT LOSS AND CANCER
CACHEXIA 2650 NUTRITION SUPPORT FOR WEIGHT LOSS AND CANCER CACHEXIA 2652
NUTRITION AND TUMOR GROWTH 2652 NUTRITIONAL ASSESSMENT OF THE CANCER
PATIENT 2652 INDICATIONS FOR NUTRITION SUPPORT 2652 PARENTERAL VERSUS
ENTERAL NUTRITION IN CANCER PATIENTS 2652 SPECIFIC INDICATIONS FOR THE
USE OF TOTAL PARENTERAL NUTRITION IN THE CANCER PATIENT 2653 IMPROVING
THE EFFICACY OF CURRENT FEEDING REGIMENS 2658 TECHNIQUES OF PROVIDING
NUTRITIONAL SUPPORT 2659 CONCLUSION 2662 SECTION 3 SEXUAL PROBLEMS 2662
PATRICIA A. GANZ MARK S. LITWIN BETH E. MEYEROWITZ SEXUAL HEALTH AND
PHYSIOLOGY 2662 SEXUAL PROBLEMS AND THEIR PREVALENCE AMONG THE GENERAL
POPULATION IMPACT OF CANCER AND ITS TREATMENT ON SEXUAL HEALTH 2664
SPECIFIC TREATMENTS 2665 SEXUAL PROBLEMS ASSOCIATED WITH SPECIFIC
CANCERS 2668 STRATEGIES FOR ASSESSMENT AND INTERVENTION 2672 CONCLUSION
2673 2663 SECTION 4 GENETIC COUNSELING 2676 ELLEN T. MATLOFF WHY IS
CANCER GENETIC COUNSELING NECESSARY? 2676 WHO IS A CANDIDATE FOR CANCER
GENETIC COUNSELING? 2677 COMPONENTS OF THE CANCER GENETIC COUNSELING
SESSION 2677 ISSUES IN CANCER GENETIC COUNSELING 2680 FUTURE DIRECTIONS
2682 LXX CONTENTS SECTION 5 PSYCHOLOGICAL ISSUES 2683 BETH L. DINOFF
JOHN L. SHUSTER PHASES OF ILLNESS 2683 PSYCHOLOGICAL COMPLICATIONS OF
CANCER 2685 THERAPIES 2688 SECTION 6 COMMUNITY RESOURCES 2691 BONNIE A.
INDECK INITIAL DIAGNOSIS OF CANCER 2692 SOCIAL SUPPORT NETWORK 2692
EMOTIONAL SUPPORT 2692 INFORMATION SUPPORT 2693 INTERNET 2693 COMPUTER
GROUPS 2694 INSTRUMENTAL SUPPORT 2694 TRENDS AFFECTING DEMAND FOR
COMMUNITY SERVICES 2695 SURVIVORSHIP 2696 APPENDIX: COMMON COMMUNITY
RESOURCES 2696 SECTION 7 SPECIALIZED CARE OF THE TERMINALLY III 2702
JANET L. ABRAHM DISCUSSING PROGNOSIS 2702 ADVANCE CARE PLANNING 2703
HOPE 2703 BARRIERS THAT INHIBIT ADVANCE CARE PLANNING DISCUSSIONS 2704
CURIOSITY 2704 HEALING VERSUS CURING 2704 HOW TO TELL THE CHILDREN 2704
CULTURAL/RELIGIOUS CONSIDERATIONS 2705 CARE WITHOUT CHEMOTHERAPY 2706
PALLIATIVE CARE PROGRAM 2706 HOSPICE PROGRAMS 2707 RELIEF OF SUFFERING
2708 THE FINAL DAYS 2724 AFTER THE DEATH 2725 GRIEF AND BEREAVEMENT 2725
CONCLUSION 2727 56 REHABILITATION OF THE CANCER PATIENT 2719 LYNN H.
GERBER MARY M. VARGO REBECCA G. SMITH IMPACT OF CANCER TREATMENT ON
FUNCTION 2720 REHABILITATION INTERVENTIONS 2725 CONTENTS LV L
REHABILITATION HOSPITALIZATION AND BASIC FUNCTIONAL INDEPENDENCE 2732
VOCATIONAL ISSUES 2733 REHABILITATION TREATMENTS OF SPECIFIC TUMORS 2734
57 SOCIETAL ISSUES IN ONCOLOGY SECTION 1 2747 ETHICAL ISSUES 2747
CHRISTOPHER K. DAUGHERTY ETHICAL ISSUES IN CLINICAL CARE IN ONCOLOGY
2747 ETHICAL ISSUES IN CANCER CLINICAL TRIALS 2752 CONCLUSION 2757 2760
2761 SECTION 2 ECONOMIC ISSUES 2759 ALBERT B. EINSTEIN, JR. U.S. HEALTH
CARE ECONOMY 2759 MEDICARE COST-CONTAINMENT EFFORTS 2759 MEDICARE
REIMBURSEMENT FOR CANCER SERVICES MEDICAID COST-CONTAINMENT EFFORTS 2762
INSURANCE INDUSTRY COST-CONTAINMENT EFFORTS HOSPITAL ECONOMIC ISSUES
2762 PHYSICIAN ECONOMIC ISSUES 2762 NATIONAL CANCER INSTITUTE-DESIGNATED
AND UNIVERSITY CANCER CENTERS ECONOMIC ISSUES 2763 CLINICAL RESEARCH
2763 IMPACT OF GENOMICS 2764 COMPLEMENTARY AND ALTERNATIVE MEDICINE 2765
STANDARDIZATION OF PRACTICE 2765 HEALTH ECONOMICS AND THE ECONOMIC
BURDEN OF CANCER 2765 THE FUTURE 2766 SECTION 3 REGULATORY ISSUES 2767
GRANT A. WILLIAMS PATRICIA KEEGAN NEIL R. P. OGDEN RICHARD PAZDUR ROBERT
TEMPLE MARK MCCLELLAN HISTORY OF U.S. FOOD AND DRUG ADMINISTRATION
REGULATION OF DRUGS AND BIOLOGIES 2767 U.S. FOOD AND DRUG ADMINISTRATION
OVERSIGHT OF CLINICAL TRIALS FOR DRUGS AND BIOLOGIES 2768 BASIS FOR
CANCER DRUG APPROVAL 2769 DRUG SAFETY REPORTING AND EVALUATION 2773
ACCESS TO INVESTIGATIONAL DRUGS 2773 BIOLOGIC DRUG PRODUCTS: SPECIAL
CONSIDERATIONS 2773 REGULATION OF DEVICES FOR CANCER TREATMENT AND
DIAGNOSIS 2774 U.S. FOOD AND DRUG ADMINISTRATION INITIATIVES AND
GUIDANCES EXPEDITING APPROVAL OF CANCER DRUGS, BIOLOGIES, AND DEVICES
2776 IXXLI CONTENTS SECTION 4 TELEMEDICINE 2777 RICHARD M. SATAVA
JONATHAN D. LINKOUS JAY H. SANDERS APPLICATIONS OF TELEMEDICINE 2778
TELEMEDICINE IN OTHER COUNTRIES 2779 TELEMEDICINE IN ONCOLOGY
CARE*CURRENT PRACTICES 2779 TELESURGERY 2779 TELEMEDICINE IMPACT ON
NATIONAL MEDICAL POLICY 2780 BARRIERS AND CHALLENGES 2780 CONCLUSION
2782 SECTION 5 INTERNATIONAL DIFFERENCES IN ONCOLOGY 2782 OLIVIER RIXE
PETER HARPER DAVID KHAYAT DEVELOPING NATIONS 2782 CANCERS AND MORTALITY:
DIFFERENCES IN THE MORE DEVELOPED COUNTRIES 2782 SCREENING 2783
ANTICANCER DRUG DEVELOPMENT THROUGHOUT THE WORLD 2784 DRUG APPROVAL
PROCESS 2784 CANCER TREATMENT STRATEGY: EUROPEAN AND UNITED STATES
DIFFERENCES 2784 DIFFERENCES IN CANCER SURVIVAL 2784 ACCESS TO CANCER
CARE IN DEVELOPED NATIONS 2785 TRAINING AS AN ONCOLOGIST 2786 RESEARCH
2786 TRUTH TELLING : DIFFERENCES BETWEEN NATIONS 2786 CANCER IN THE
ELDERLY 2787 CONCLUSION 2787 SECTION 6 THE NATIONAL CANCER PROGRAM 2788
ANDREW C. VON ESCHENBACH NATIONAL CANCER INSTITUTE AS STEWARD OF THE
NATIONAL CANCER PROGRAM 2789 HARNESSING THE POWER OF MOLECULAR
EPIDEMIOLOGY 2789 DEVELOPING AN INTEGRATIVE UNDERSTANDING OF CANCER
BIOLOGY 2790 PROVIDING BIOINFORMATICS INFRASTRUCTURE 2790 DEVELOPING
PREVENTION, EARLY DETECTION, AND PREDICTION APPROACHES 2790 FACILITATING
THE DEVELOPMENT OF CANCER INTERVENTIONS 2792 CREATING AN INTEGRATED
CLINICAL TRIALS SYSTEM 2792 OVERCOMING HEALTH DISPARITIES 2792 A
CRITICAL ENTERPRISE-WIDE OPPORTUNITY: TECHNOLOGY DEVELOPMENT AND
INTEGRATION 2792 INTEGRATIVE COMPUTATIONAL BIOLOGY AND BIOINFORMATICS
2792 ADVANCED IMAGING 2792 BIOENGINEERING AND ADVANCED PROTOTYPING 2792
DEVELOPMENT AND PRECLINICAL TESTING OF PREVENTION AND THERAPEUTIC AGENTS
2792 SHARED RESEARCH RESOURCES 2793 CONCLUSION 2793 CONTENTS LXXIII 58
INFORMATION SYSTEMS IN ONCOLOGY 2795 DANIEL R. MASYS THE INTERNET 2796
ELECTRONIC MEDICAL RECORDS 2799 CONCLUSION 2802 59 COMPLEMENTARY,
ALTERNATIVE, AND INTEGRATIVE THERAPIES IN CANCER CARE 2805 ETHAN M.
BASCH CATHERINE E. ULBRICHT BACKGROUND 2805 SAFETY CONCERNS 2806
PATIENT-CLINICIAN COMMUNICATION 2808 SPECIFIC COMPLEMENTARY AND
ALTERNATIVE MEDICINE THERAPIES 2809 THERAPIES USED FOR CANCER TREATMENT
AND SECONDARY PREVENTION 2809 THERAPIES USED FOR SUPPORTIVE CARE 2822
THERAPIES USED FOR PRIMARY CANCER PREVENTION 2823 PART 4 NEWER
APPROACHES IN CANCER TREATMENT 60 GENE THERAPY 2819 PATRICK HWU METHODS
OF GENE TRANSFER 2829 GENE MARKING STUDIES 2824 GENETIC MODIFICATION OF
THE IMMUNE RESPONSE 2826 MODIFICATION OF TUMORS WITH GENES THAT HAVE
DIRECT ANTITUMOR EFFECTS 2830 SELECTIVE REPLICATION OF VIRUS IN TUMORS
2832 INTRODUCTION OF GENES INTO NORMAL TISSUES TO PROTECT THEM FROM
CHEMOTHERAPY OR RADIOTHERAPY 2832 ANTIANGIOGENIC GENE THERAPY 2833
MOLECULAR IMAGING OF GENE-MODIFIED CELLS 2834 CONCLUSION 2834 61 CANCER
VACCINES 2839 SECTION 1 PREVENTIVE VACCINES 2839 DOUGLAS R. LOWY ! JOHN
T. SCHILLER BACKGROUND 2839 LXXIV CONTENTS INFECTIOUS AGENTS AND CANCER
2839 PROPHYLACTIC VERSUS THERAPEUTIC VACCINATION 2842 HEPATITIS B VIRUS
2842 HUMAN PAPILLOMAVIRUS 2843 HELICOBACTER PYLORI 2845 SECTION 2
THERAPEUTIC VACCINES 2846 NICHOLAS P. RESTIFO JONATHAN J.LEWIS
ELICITATION OF TUMOR-SPECIFIC IMMUNE RESPONSES 2846 IDENTIFICATION OF
TUMOR-ASSOCIATED ANTIGENS SUITABLE FOR THERAPEUTIC TARGETING 2846
ENHANCEMENT OF TUMOR ANTIGEN IMMUNOGENICITY BY MODIFICATION OF EPITOPE
SEQUENCES 2847 EARLY MODELS USING THERAPEUTIC CANCER VACCINES 2848
CONSISTENT INCREASES IN TUMOR-SPECIFIC T CELLS WITHOUT CONSISTENT
CLINICAL RESPONSES 2848 HOW ARE WE DOING IN CLINICAL TRIALS? 2848
LESSONS FROM MELANOMA 2849 CLINICAL TRIAL DATA 2850 IMMUNE RESPONSES DO
NOT ALWAYS TRANSLATE INTO CLINICAL RESPONSES* PROPOSED MECHANISMS OF
TUMOR ESCAPE 2853 FUTURE DIRECTIONS: A FOCUS ON T-CELL ACTIVATION AND
DEATH 2853 CONCLUSION 2854 62 CELL TRANSFER THERAPY 2857 MARK E. DUDLEY
STEVEN A. ROSENBERG BACKGROUND 2857 PRECLINICAL STUDIES OF ADOPTIVE CELL
TRANSFER 2858 CLINICAL TRIALS 2858 TUMOR-INFILTRATING LYMPHOCYTES 2860
ADOPTIVE CELL TRANSFER THERAPY AFTER LYMPHODEPLETING CHEMOTHERAPY IN
PATIENTS WITH MELANOMA 2860 ADDITIONAL STUDIES 2862 63 ANTIANGIOGENESIS
AGENTS 2865 JUDAH FOLKMAN ANGIOGENIC SWITCH 2865 ENDOGENOUS ANGIOGENESIS
INHIBITORS 2867 RATIONALE FOR ANTIANGIOGENIC THERAPY OF CANCER 2867
ANTIANGIOGENIC (METRONOMIC) CHEMOTHERAPY 2869 I FUTURE DIRECTIONS 2879
CONTENTS LXXV 64 FOCUSED ULTRASOUND 2883 FERENC A. JOLESZ KULLERVO H.
HYNYNEN FUNDAMENTAL PRINCIPLES OF FOCUSED ULTRASOUND SURGERY 2883
INTERACTION BETWEEN TISSUE AND THE ULTRASOUND BEAM 2884 MAGNETIC
RESONANCE IMAGING GUIDANCE FOR THERMAL ABLATIONS 2884 MAGNETIC RESONANCE
IMAGING-GUIDED FOCUSED ULTRASOUND THERAPY DELIVERY SYSTEMS 2885 CLINICAL
APPLICATIONS 2886 CONCLUSION 2889 65 ANTISENSE INHIBITION OF GENE
EXPRESSION 2891 C. A. STEIN LUBA BENIMETSKAYA SRIDHAR MANI
OLIGONUCLEOTIDE STABILITY AND EFFICACY: THE ROLE OF PHOSPHOROTHIOATES
2892 MECHANISM OF ACTION OF THE ANTISENSE EFFECT 2894 DELIVERY OF
OLIGONUCLEOTIDES INTO CELLS 2895 PHARMACOKINETICS 2896 CLINICAL STUDIES
2896 CLINICAL TRIALS OF G3139 2897 INDEX 1-1
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV019688358 |
| classification_rvk | XH 1200 |
| ctrlnum | (OCoLC)65978431 (DE-599)BVBBV019688358 |
| discipline | Medizin |
| edition | 7. ed. |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01775nam a2200481 c 4500</leader><controlfield tag="001">BV019688358</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080602 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">050207s2005 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0781744504</subfield><subfield code="9">0-781-74450-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)65978431</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV019688358</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 1200</subfield><subfield code="0">(DE-625)152866:</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer</subfield><subfield code="b">principles & practice of oncology</subfield><subfield code="c">ed. by Vincent T. DeVita ...</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">7. ed.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia u.a.</subfield><subfield code="b">Lippincott Williams & Wilkins</subfield><subfield code="c">2005</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">IXXV, 2898, 158 S.</subfield><subfield code="b">zahlr. Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Literaturangaben</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neoplasias</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncologia</subfield><subfield code="2">larpcal</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oncology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebsforschung</subfield><subfield code="0">(DE-588)4165564-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Krebsforschung</subfield><subfield code="0">(DE-588)4165564-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">DeVita, Vincent T.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HEBIS Datenaustausch Mainz</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013016209&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-013016209</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| id | DE-604.BV019688358 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T20:03:51Z |
| institution | BVB |
| isbn | 0781744504 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-013016209 |
| oclc_num | 65978431 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | IXXV, 2898, 158 S. zahlr. Ill., graph. Darst. |
| publishDate | 2005 |
| publishDateSearch | 2005 |
| publishDateSort | 2005 |
| publisher | Lippincott Williams & Wilkins |
| record_format | marc |
| spelling | Cancer principles & practice of oncology ed. by Vincent T. DeVita ... 7. ed. Philadelphia u.a. Lippincott Williams & Wilkins 2005 IXXV, 2898, 158 S. zahlr. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Literaturangaben Neoplasias larpcal Oncologia larpcal Cancer Neoplasms Oncology Onkologie (DE-588)4075658-0 gnd rswk-swf Krebsforschung (DE-588)4165564-3 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Onkologie (DE-588)4075658-0 s DE-604 Krebs Medizin (DE-588)4073781-0 s Krebsforschung (DE-588)4165564-3 s 1\p DE-604 DeVita, Vincent T. Sonstige oth HEBIS Datenaustausch Mainz application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013016209&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Cancer principles & practice of oncology Neoplasias larpcal Oncologia larpcal Cancer Neoplasms Oncology Onkologie (DE-588)4075658-0 gnd Krebsforschung (DE-588)4165564-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4075658-0 (DE-588)4165564-3 (DE-588)4073781-0 |
| title | Cancer principles & practice of oncology |
| title_auth | Cancer principles & practice of oncology |
| title_exact_search | Cancer principles & practice of oncology |
| title_full | Cancer principles & practice of oncology ed. by Vincent T. DeVita ... |
| title_fullStr | Cancer principles & practice of oncology ed. by Vincent T. DeVita ... |
| title_full_unstemmed | Cancer principles & practice of oncology ed. by Vincent T. DeVita ... |
| title_short | Cancer |
| title_sort | cancer principles practice of oncology |
| title_sub | principles & practice of oncology |
| topic | Neoplasias larpcal Oncologia larpcal Cancer Neoplasms Oncology Onkologie (DE-588)4075658-0 gnd Krebsforschung (DE-588)4165564-3 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Neoplasias Oncologia Cancer Neoplasms Oncology Onkologie Krebsforschung Krebs Medizin |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013016209&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT devitavincentt cancerprinciplespracticeofoncology |